Teva Pharmaceutical Industries Limited (TEVA) 10-K 10 Feb 23 2022 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Annual Report	true
Entity Registrant Name	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Entity Central Index Key	0000818686
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding	1,110,899,783
Title of 12(b) Security	American Depositary Shares, each representing one Ordinary Share
Trading Symbol	TEVA
Security Exchange Name	NYSE
Entity File Number	001-16174
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	124 Dvora HaNevi’a St.
Entity Address, City or Town	Tel Avi
Entity Address, Postal Zip Code	6944020
Entity Address, Country	IL
City Area Code	+972 (3)
Local Phone Number	914-8213
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Public Float		$ 7.3
ICFR Auditor Attestation Flag	true
Auditor Name	Kesselman & Kesselman
Auditor Firm ID	1309
Auditor Location	Israel

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2022		Dec. 31, 2021
Current assets:
Cash and cash equivalents		$ 2,801		$ 2,165
Accounts receivables, net of allowance for credit losses of $91 million and $90 million as of December 31, 2022 and December 31, 2021, respectively		3,696		4,529
Inventories		3,833		3,818
Prepaid expenses		1,162		1,075
Other current assets		549		965
Assets held for sale		10		19
Total current assets		12,051		12,573
Deferred income taxes		1,453		596
Other non-current assets		441		515
Property, plant and equipment, net		5,739		5,982
Operating lease right-of-use assets		419		495
Identifiable intangible assets, net		6,270		7,466
Goodwill	[1]	17,633	[2]	20,040
Total assets		44,006		47,666
Current liabilities:
Short-term debt		2,109		1,426
Sales reserves and allowances		3,750		4,241
Accounts payables		1,887		1,686
Employee-related obligations		566		563
Accrued expenses		2,151		2,208
Other current liabilities		1,005		903
Total current liabilities		11,469		11,027
Long-term liabilities:
Deferred income taxes		548		784
Other taxes and long-term liabilities		3,847		2,578
Senior notes and loans		19,103		21,617
Operating lease liabilities		349		416
Total long-term liabilities		23,846		25,395
Commitments and contingencies, see note 12
Total liabilities		35,315		36,422
Teva shareholders' equity:
Ordinary shares of NIS 0.10 par value per share; December 31, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,217 million shares and 1,209 million shares, respectively		57		57
Additional paid-in capital		27,688		27,561
Accumulated deficit		(12,882)		(10,529)
Accumulated other comprehensive loss		(2,838)		(2,683)
Treasury shares as of December 31, 2021 and December 31, 2020: 106 million ordinary shares		(4,128)		(4,128)
Stockholders' equity attributable to Teva shareholders		7,897		10,278
Non-controlling interests		794		966
Total equity		8,691		11,244
Total liabilities and equity		$ 44,006		$ 47,666
[1]Accumulated goodwill impairment as of December 31, 2022, December 31, 2021 and December 31, 2020 was approximately $27.6 billion, $25.6 billion and $25.6 billion, respectively.[2]As of December 31, 2022, “Other” includes $1,293 million goodwill balance related to Teva’s API reporting unit.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) $ in Millions	Dec. 31, 2022 USD ($) shares	Dec. 31, 2022 ₪ / shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 ₪ / shares
Allowance for credit losses | $	$ 91		$ 90
Common stock, par or stated value per share | ₪ / shares		₪ 0.1		₪ 0.1
Ordinary shares, authorized	2,495,000,000		2,495,000,000
Ordinary shares, issued	1,217,000,000		1,209,000,000
Treasury shares	106,000,000		106,000,000

Consolidated Statements of Inco

Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net revenues	$ 14,925	$ 15,878	$ 16,659
Cost of sales	7,952	8,284	8,933
Gross profit	6,973	7,594	7,726
Research and development expenses, net	838	967	997
Selling and marketing expenses	2,265	2,429	2,498
General and administrative expenses	1,180	1,099	1,173
Intangible assets impairments	355	424	1,502
Goodwill impairment	2,045	0	4,628
Other asset impairments, restructuring and other items	414	341	479
Legal settlements and loss contingencies	2,082	717	60
Other income	(107)	(98)	(40)
Operating (loss) income	(2,099)	1,716	(3,572)
Financial expenses – net	966	1,058	834
Income (loss) before income taxes	(3,065)	658	(4,406)
Income taxes (benefit)	(638)	211	(168)
Share in (profits) losses of associated companies – net	(21)	(9)	(138)
Net income (loss)	(2,406)	456	(4,099)
Net income (loss) attributable to non-controlling interests	(53)	39	(109)
Net income (loss) attributable to Teva	$ (2,353)	$ 417	$ (3,990)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ (2.12)	$ 0.38	$ (3.64)
Diluted	$ (2.12)	$ 0.38	$ (3.64)
Weighted average number of shares (in millions):
Basic	1,110	1,102	1,095
Diluted	1,110	1,107	1,095

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net income (loss)	$ (2,406)	$ 456	$ (4,099)
Other comprehensive income (loss), net of tax:
Currency translation adjustment	(356)	(462)	(69)
Unrealized gain (loss) on derivative financial instruments, net	29	39	57
Unrealized gain (loss) on defined benefit plans, net	57	32	(18)
Total other comprehensive income (loss)	(270)	(391)	(30)
Total comprehensive income (loss)	(2,676)	65	(4,129)
Comprehensive income (loss) attributable to non-controlling interests	(169)	(68)	(53)
Comprehensive income (loss) attributable to Teva	$ (2,507)	$ 133	$ (4,076)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Millions	Total	Ordinary Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Shares [Member]	Total Teva Shareholders' Equity [Member]	Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2019	$ 15,063	$ 56	$ 27,312	$ (6,956)	$ (2,312)	$ (4,128)	$ 13,972	$ 1,091
Beginning balance, shares at Dec. 31, 2019		1,198,000,000
Net income (loss)	(4,099)			(3,990)			(3,990)	(109)
Other comprehensive income (loss)	(30)				(86)		(86)	56
Issuance of Treasury Shares	1						1
Issuance of Shares, shares		4
Stock-based compensation expense	129		129				129
Transactions with non-controlling interests	(2)							(2)
Ending balance at Dec. 31, 2020	11,061	$ 57	27,443	(10,946)	(2,399)	(4,128)	10,026	1,035
Ending balance, shares at Dec. 31, 2020		1,202,000,000
Net income (loss)	456			417			417	39
Other comprehensive income (loss)	(391)				(283)		(283)	(107)
Issuance of Shares, shares		7,000,000
Stock-based compensation expense	119		119				119
Transactions with non-controlling interests	(2)							(2)
Ending balance at Dec. 31, 2021	11,244	$ 57	27,561	(10,529)	(2,683)	(4,128)	10,278	966
Ending balance, shares at Dec. 31, 2021		1,209,000,000
Net income (loss)	(2,406)			(2,353)			(2,353)	(53)
Other comprehensive income (loss)	(270)				(154)		(154)	(116)
Issuance of Shares, value	1		1				1
Issuance of Shares, shares		8,000,000
Stock-based compensation expense	124		124				124
Transactions with non-controlling interests	(2)							(2)
Ending balance at Dec. 31, 2022	$ 8,691	$ 57	$ 27,688	$ (12,882)	$ (2,838)	$ (4,128)	$ 7,897	$ 794
Ending balance, shares at Dec. 31, 2022		1,217,000,000

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Maximum [Member] | Ordinary Shares [Member]
Exercise of options by employees and vested RSUs	$ 0.5	$ 0.5	$ 0.5

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities:
Net income (loss)	$ (2,406)	$ 456	$ (4,099)
Adjustments to reconcile net income (loss) to net cash provided by operations:
Impairment of goodwill, long-lived assets and assets held for sale	2,447	584	6,546
Depreciation and amortization	1,308	1,330	1,557
Net change in operating assets and liabilities	1,257	(1,701)	(2,188)
Deferred income taxes — net and uncertain tax positions	(1,059)	(120)	(696)
Stock-based compensation	124	119	129
Other items	(91)	16	100
Research and development in process	0	10	80
Net loss (gain) from investments and from sale of business and long lived assets	10	104	(213)
Net cash provided by (used in) operating activities	1,590	798	1,216
Investing activities:
Beneficial interest collected in exchange for securitized trade receivables	1,140	1,648	1,405
Proceeds from sale of business and long lived assets	68	311	67
Purchases of property, plant and equipment	(548)	(562)	(578)
Purchases of investments and other assets	(1)	(47)	(55)
Proceeds from sale of investments	4	172	12
Other investing activities	0	1	12
Acquisitions of businesses, net of cash acquired	(7)	0	0
Net cash provided by (used in) investing activities	656	1,523	863
Financing activities:
Repayment of senior notes and loans and other long-term liabilities	(1,369)	(6,649)	(1,871)
Proceeds from senior notes, net of issuance costs	0	4,974	0
Proceeds from short term debt	0	700	550
Repayment of short term debt	0	(700)	(559)
Redemption of convertible debentures	0	(491)	0
Other financing activities	(118)	(6)	(5)
Net cash provided by (used in) financing activities	(1,487)	(2,172)	(1,885)
Translation adjustment on cash and cash equivalents	(123)	(128)	8
Net change in cash, cash equivalents and restricted cash	636	21	202
Balance of cash, cash equivalents and restricted cash at beginning of year	2,198	2,177	1,975
Balance of cash, cash equivalents and restricted cash at end of year	2,834	2,198	2,177
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheet:
Cash and cash equivalents	2,801	2,165	2,177
Restricted cash included in other current assets	33	33	0
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	2,834	2,198	2,177
Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized trade receivables	1,189	1,635	1,397
Cash paid during the year for:
Interest	948	913	846
Income taxes, net of refunds	543	495	709
Net change in operating assets and liabilities:
Other current assets	(828)	(2,271)	(1,473)
Trade payables, accrued expenses, employee-related obligations and other liabilities	1,914	764	(463)
Trade receivables net of sales reserves and allowances	334	(574)	(293)
Inventories	(163)	380	41
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	$ 1,257	$ (1,701)	$ (2,188)

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies	NOTE 1—Significant accounting policies: a. General: Operations Teva Pharmaceutical Industries Limited (the “Parent Company”), headquartered in Israel, together with its subsidiaries and associated companies (the “Company,” “Teva” or the “Group”), is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The majority of the Group’s revenues are in the United States and Europe. Basis of presentation and use of estimates The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). In preparing the Company’s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. In preparing the Company’s consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of IPR&D assets, marketed product rights and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could be impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. Government actions taken to address macroeconomic developments, as well as their economic impact on Teva’s third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. In February 2022, Russia launched an invasion of Ukraine. As of the date of these consolidated financial statements, sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva’s International Markets segment results. Teva has no manufacturing or R&D facilities in these markets. As part of the Company’s annual goodwill analysis performed in the second quarter of 2022, it identified an increase in the discount rate, which led to a goodwill impairment charge in its International Markets reporting unit. This increase was a result of an increase in certain components of the discount rate that were partially attributed to higher risk associated with country-specific characteristics of several countries, such as Russia, that might be a consequence of the conflict. Other than its impact on the goodwill impairment charge described above, during the year ended December 31, 2022, the impact of the Russia-Ukraine conflict on Teva’s results of operations and financial condition was immaterial. See also note 7. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. Functional currency A major part of the Group’s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (“dollar” or “$”). The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results net of related income taxes are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). Principles of consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and variable interest entities (“VIEs”) for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders’ interests are shown as non-controlling For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated. b. New accounting pronouncements Recently adopted accounting pronouncements In November 2021, the FASB issued ASU 2021-10 in-scope In August 2020, the FASB issued ASU 2020-06 470-20) In March 2020, the FASB issued ASU 2020-04 adoption of this guidance did not have a material impact on the Company’s consolidated financial results of operations, financial position or cash flows. Recently issued accounting pronouncements, not yet adopted In September 2022, the FASB issued ASU 2022-04 405-50)”. In October 2021, the FASB issued ASU 2021-08 c. Acquisitions: Teva’s consolidated financial statements include the operations of acquired businesses from the date of the acquisition’s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed unless it has an alternative future use. Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is re-measured d. Collaborative arrangements: Collaborative arrangements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues are recorded on a net basis. e. Equity investments: The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative prescribed within ASU 2016-01 f. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. g. Cash and cash equivalents: All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents. h. Restricted cash: Restricted cash represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet under other current assets. i. Accounts Receivables: Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. Write-off j. Concentration of credit risks: Most of Teva’s cash and cash equivalents (which, along with investment in securities, totaled $2,817 million at December 31, 2022) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 47% of Teva’s consolidated revenues in 2022. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. k. Inventories: Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. Inventories acquired in a business combination are stepped-up l. Long-lived assets: Teva’s long-lived, non-current right-of-use Goodwill Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any non-controlling assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. The goodwill impairment test is performed according to the following principles: 1. An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. 2. If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value is recognized. An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company’s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company’s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. Identifiable intangible assets Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (“FDA”) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (“S&M”) expenses when separable. Indefinite life intangible assets are mainly comprised of IPR&D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. IPR&D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset’s estimated life, calculates the undiscounted value of the asset’s or asset group’s cash flows and compares such value against the asset’s or asset group’s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. For indefinite life intangible assets, Teva performs an impairment test annually in the second quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Teva determines the fair value of the asset based on discounted cash flows and records an impairment loss if its book value exceeds fair value. In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company’s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i) for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii) for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. Property, plant and equipment Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly 20 years; and other assets, between 5 to 10 years. For property, plant and equipment and lease right-of-use Lease right-of-use See note 8 and note 1cc for further discussion. m. Contingencies: The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are reasonably estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. When applicable, the Company classifies the effect that the passage of time had on the net present value of a discounted legal accrual as legal expenses. Legal costs are expensed as incurred. The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved. n. Treasury shares: Treasury shares are presented as a reduction of Teva shareholders’ equity and carried at their cost to Teva, under treasury shares. 103 o. Stock-based compensation: Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (“RSUs”) and performance share units (“PSUs”). The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option’s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards and RSUs to expense over the vesting period on a straight-line basis. Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting. Teva records forfeitures for share-based awards, RSUs and PSUs as they occur. If an employee forfeits an award because he fails to complete the requisite service period, the Company will reverse the compensation cost previously recognized in the period the award is forfeited. p. Deferred income taxes: Deferred income taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as non-current. Tax has not been provided on the following items: 1. Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company’s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. 2. Amounts of tax-exempt q. Uncertain tax positions: Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly re-evaluates Provisions for uncertain tax positions, whereas Teva has net o ting losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss. r. Derivatives and hedging: The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company’s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. Derivative instruments are recognized on the balance sheet at their fair value. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses, net in the statements of income in the period that the changes in fair value occur. For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. For derivative instruments that are designated as net-investment For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. Derivative instruments that do not qualify for hedge accounting are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses, net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. s. Revenue recognition: A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“performance obligations”), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (“SR&A”) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&A components and how they are estimated, see “Variable Consideration” below. Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&M expenses. Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one year or less, based on the practical expedient. The Company’s credit terms to customers are, on average, between thirty and . The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. Nature of revenue streams Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. Licensing arrangements performance obligations generally include intellectual property (“IP”) rights, certain R&D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct – i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company’s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company’s IP. Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Revenues from licensing arrangements included royalty income of $212 million, $160 million and $129 million for the years ended December 31, 2022, 2021 and 2020, respectively. Distribution revenues are derived from sales of third-party products for which the Company acts as distributor, mostly in the United States via Anda and in Israel via Salomon Levin and Elstein Ltd. (SLE). In the United States, the Company is the principal in these arrangements and therefore records revenue on a gross basis as it controls the promised goods before transferring these goods to the customer. In Israel, the Company is the agent in these arrangements and therefore records revenue on a net basis as it has no discretion in establishing prices for any specified goods or services, limited inventory risk and is not primarily responsible for contract fulfillment. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. Other revenues are primarily comprised of contract manufacturing services, sales of medical devices and other miscellaneous items. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped, once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. Trade receivables and contract liabilities Trade receivables are presented net of allowance for credit losses, which include amounts billed and currently due from customers. Contract liabilities are mainly comprised of deferred revenues (defined as obligations to provide products or services to customers when payment has been made in advance and delivery or performance has not yet occurred), which were immaterial as of December 31, 2022 and 2021. Variable consideration Variable consideration mainly includes SR&A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated: Rebates Rebates are primarily related to volume incentives and are offered to key customers to promote loyalty. These rebate programs provide that, upon the attainment of pre-established Medicaid and Other Governmental Rebates Pharmaceutical manufacturers whose products are covered by the Medicaid program are required to provide a rebate to each state as a percentage of their average manufacturer’s price for generic products dispensed and “best price” for innovative products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. Chargebacks The Company has arrangements with various third parties, such as managed care organizations and drug store chains, establishing prices for certain of Teva’s products. While these arrangements are made between the Company and the customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with Teva’s concurrence, which establish the pricing for certain products which the wholesalers provide. Under either arrangement, Teva will issue a credit (referred to as a “chargeback”) to the wholesaler for the difference between the invoice price to the wholesaler and the customer’s contract prices. Provisions for chargebacks involve estimates of contract prices of over 2,000 products and multiple contracts with multiple wholesalers. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inv

Certain transactions

Certain transactions	12 Months Ended
	Dec. 31, 2022
Certain transactions	NOTE 2—Certain transactions: The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company’s most significant agreements of this nature are summarized below. MODAG In October 2021, Teva announced a license agreement with MODAG GmbH (“Modag”) that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag’s lead compound (TEV-56286) (TEV-56287). TEV-56286 TEV-56286. Alvotech In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to Humira ® ® $ million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. Alvotech was previously involved in litigation involving certain IP and trade secrets claims filed by Abbvie in relation to Alvotech’s proposed biosimilar to Humira ® ® ® ® Eli Lilly and Alder BioPharmaceuticals In December 2018, Teva entered into an agreement with Eli Lilly & Co. (“Lilly”) resolving the European Patent Office opposition they had filed against Teva’s AJOVY patents. The settlement agreement with Lilly also resolved Lilly’s action to revoke the patent protecting AJOVY in the United Kingdom. On January non-exclusive Otsuka On May 12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (“Otsuka”) providing Otsuka with an exclusive license to develop and commercialize AJOVY in Japan. Otsuka paid Teva an upfront payment of $50 million in consideration for the transaction. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $15 million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August 30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of $35 million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka also pays Teva royalties on AJOVY sales in Japan. Takeda In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”), for the research, development, manufacture and commercialization of Attenukine ® Regeneron In September 2016, Teva and Regeneron Pharmaceuticals, Inc. (“Regeneron”) entered into a collaborative agreement to develop and commercialize Regeneron’s pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&D costs of approximately $1 billion. Teva made an upfront payment of $250 million to Regeneron in 2016 and additional payments for achievement of development milestones in an aggregate amount of $120 million were paid during 2017 and 2018. In October 2022, development of fasinumab for the treatment of osteoarthritic pain was discontinued. MedinCell In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable (“LAI”) products. The lead product candidate selected was risperidone LAI (TV-46000) million in respect of risperidone LAI. Teva will also pay MedinCell royalties on net sales. In April 2022, the FDA issued a CRL regarding the NDA for risperidone LAI. Teva resubmitted the NDA in October 2022 and awaits the FDA’s response. The second selected product candidate is TEV-44749, million milestone payment was paid to MedinCell which was recognized as R&D expenses. MedinCell may become eligible for further milestones and royalties on sales of TEV-44749. Assets and Liabilities Held For Sale: General Assets held for sale as of December 31, 2022 included certain manufacturing assets that were expected to be sold within the next year. Assets and liabilities held for sale as of December 31, 2021 included certain manufacturing assets sold during the first and second quarters of 2022. The table below summarizes all of Teva’s assets and liabilities included as held for sale as of December 31, 2022 and December 31, 2021: December 31, December 31, (U.S. $ in millions) Inventories 2 2 Property, plant and equipment, net and others 18 86 Goodwill — 7 Adjustments of assets held for sale to fair value (10 ) (76 ) Total assets of the disposal group classified as held for sale in $ 10 $ 19 Total liabilities of the disposal group classified as held for sale $ — $ (43 )

Revenue from contracts with cus

Revenue from contracts with customers	12 Months Ended
	Dec. 31, 2022
Revenue from contracts with customers	NOTE 3—Revenue from contracts with customers: Disaggregation of revenue The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. Year ended December 31, 2022 North Europe International Other Total (U.S.$ in millions) Sale of goods 5,834 4,455 1,806 671 12,766 Licensing arrangements 139 51 19 4 212 Distribution 1,471 1 46 — 1,519 Other 8 18 33 370 428 $ 7,452 $ 4,525 $ 1,903 $ 1,045 $ 14,925 Year ended December 31, 2021 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,394 4,807 1,889 739 13,829 Licensing arrangements 92 50 13 4 160 Distribution 1,323 1 65 — 1,390 Other (1 ) 27 65 408 500 $ 7,809 $ 4,886 $ 2,032 $ 1,151 $ 15,878 Year ended December 31, 2020 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,902 4,736 1,946 772 14,354 Licensing arrangements 84 32 9 4 129 Distribution 1,462 3 30 — 1,495 Other § (14 ) 169 527 680 $ 8,447 $ 4,757 $ 2,154 $ 1,302 $ 16,659 § Represents an amount less than $1 million. Variable consideration Variable consideration mainly includes SR&A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from t SR&A to U.S. customers comprised approximately 71% of the Company’s total SR&A as of December 3 1, Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Sales Reserves and Total (U.S.$ in millions) Balance at January 1, 2022 $ 68 $ 1,655 $ 854 $ 1,085 $ 535 $ 112 $ 4,241 $ 4,309 Provisions related to sales made in current 363 3,823 871 7,819 317 85 12,915 13,278 Provisions related to sales made in prior — (69 ) (35 ) (44 ) (3 ) (51 ) (202 (202 ) Credits and payments (364 ) (3,798 ) (1,023 ) (7,861 ) (390 ) (77 ) (13,149 (13,513 ) Translation differences — (36 ) (4 ) (8 ) (4 ) (3 ) (55 (55 ) Balance at December 31, 2022 $ 67 $ 1,575 $ 663 $ 991 $ 455 $ 66 $ 3,750 $ 3,817 Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Total (U.S.$ in millions) Balance at January 1, 2021 $ 80 $ 2,054 $ 828 $ 1,108 $ 686 $ 148 $ 4,824 $ 4,904 Provisions related to sales made in current year period 382 4,030 852 7,967 263 314 13,426 13,808 Provisions related to sales made in prior periods (9 ) (125 ) (51 ) (47 ) (60 ) (26 ) (309 ) (318 ) Credits and payments (385 ) (4,275 ) (768 ) (7,937 ) (350 ) (321 ) (13,651 ) (14,036 ) Translation differences — (29 ) (7 ) (6 ) (4 ) (3 ) (49 ) (49 ) Balance at December 31, 2021 $ 68 $ 1,655 $ 854 $ 1,085 $ 535 $ 112 $ 4,241 $ 4,309 Allowance for credit losses Accounts receivable s Pledged accounts receivables Accounts receivables, net of allowance for credit losses, include an amount of $436 million which is pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022. See note 10f.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventories	NOTE 4—Inventories: Inventories, net of reserves, consisted of the following: December 31, 2022 2021 (U.S. $ in millions) Finished products $ 1,987 $ 1,932 Raw and packaging materials 1,059 1,136 Products in process 555 587 Materials in transit and payments on account 232 163 $ 3,833 $ 3,818 11 6

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment	NOTE 5—Property, plant and equipment: Property, plant and equipment, net, consisted of the following: December 31, 2022 2021 (U.S. $ in millions) Machinery and equipment $ 5,026 $ 5,098 Buildings 2,463 2,568 Computer equipment and other assets 2,323 2,261 Assets under construction and payments on account 1,199 1,034 Land 246 262 11,257 11,223 Less—accumulated depreciation (5,518 ) (5,241 ) $ 5,739 $ 5,982 D epreciation expenses were $576 million, $528 million and $537 million in the years ended December 31, 2022, 2021 and 2020, respectively. During the years ended December 31, 2022, 2021 and 2020, Teva recorded impairments of property, plant and equipment in the amount of $47 million, $160 million and $416 million, respectively. See note 15.

Identifiable Intangible Assets

Identifiable Intangible Assets	12 Months Ended
	Dec. 31, 2022
Identifiable Intangible Assets	NOTE 6—Identifiable intangible assets: Identifiable intangible assets consisted of the following: Gross carrying amount Accumulated Net carrying amount December 31, 2022 2021 2022 2021 2022 2021 (U.S. $ in millions) Product rights $ 18,067 $ 18,815 $ 12,630 $ 12,318 $ 5,437 $ 6,497 Trade names 577 590 231 198 346 392 In-process 487 577 — — 487 577 Total $ 19,131 $ 19,982 $ 12,861 $ 12,516 $ 6,270 $ 7,466 Product rights and trade names Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various categories with a weighted average life of approximately 9 years. Amortization of intangible assets amounted to $732 million, $802 million and $1,020 million in the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022, the estimated aggregate amortization of intangible assets for the years 2023 to 2027 is as follows: 2023—$597 million; 2024—$531 million; 2025—$490 million; 2026—$493 million and 2027—$485 million. These estimates do not include the impact of IPR&D that is expected to be successfully completed and reclassified to product rights. IPR&D Teva’s IPR&D are assets that have not yet been approved in major markets. IPR&D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. Intangible assets impairment Impairments of identifiable intangible assets were $355 million, $424 million and $1,502 million in the years ended December 31, 2022, 2021 and 2020, respectively. These amounts are recorded in the statement of income (loss) under intangible assets impairments. The fair value measurement of the impaired intangible assets in 2022 is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The discount rate applied ranged from 7.25% to 11%. A probability of success factor ranging from 20% to 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&D. Impairments in 2022 consisted of: (a) Identifiable product rights of $310 million due to: (i) $256 million related to updated market assumptions regarding price and volume of products, and (ii) $54 million related to a change in Teva’s commercial plans regarding a certain program, as part of portfolio optimization efforts, which also included an inventory write-off of $108 million; and (b) IPR&D assets of $45 million, due to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date). Impairments in 2021 consisted of: (a) Identifiable product rights and trade names of $297 million due to: (i) $267 million, mainly related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States, and, (ii) $30 million related to lenalidomide (generic equivalent of Revlimid ® (b) IPR&D assets of $127 million, mainly due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. Impairments in 2020 consisted of: (a) IPR&D assets of $797 million, mainly due to: (i) $300 million related to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States; (ii) $262 million related to lenalidomide (generic equivalent of Revlimid ® and 211 (b) Identifiable product rights of $705 million, mainly due to: (i) $398 million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States; (ii) $165 million in Japan in connection with ongoing regulatory pricing reductions and generic competition; and (iii) $110 million related to a change in the assumptions regarding competition for the expected relaunch of metformin tablets.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2022
Goodwill	The changes in the carrying amount of goodwill for the years ended December 31, 2022 and 2021 were as follows: North Europe International Other Total (U.S. $ in millions) Balance as of December 31, 2020 (1) $ 6,473 $ 9,102 $ 2,362 $ 2,687 $ 20,624 Changes during the period: Goodwill reclassified as assets held for sale — (7 ) — (11 ) (18 ) Translation differences 1 (551 ) (34 ) 18 (566 ) Balance as of December 31, 2021 (1) $ 6,474 $ 8,544 $ 2,328 $ 2,694 $ 20,040 Changes during the period: Goodwill impairment — — (979 ) (1,066 ) (2,045 ) Goodwill acquired — — — 12 12 Translation differences (24 ) (242 ) (10 ) (98 ) (374 ) Balance as of December 31, 2022 (1) (*) $ 6,450 $ 8,302 $ 1,339 $ 1,542 $ 17,633 (1) Accumulated goodwill impairment as of December 31, 2022, December 31, 2021 and December 31, 2020 was approximately $27.6 billion, $25.6 billion and $25.6 billion, respectively. (*) As of December 31, 2022, “Other” includes $1,293 million goodwill balance related to Teva’s API reporting unit. Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva’s production and sale of APIs to third parties (“Teva API”) and an out-licensing Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva’s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (“WACC”), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva’s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. First Quarter Developments During the first quarter of 2022, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of March 31, 2022. Management concluded that no triggering event had occurred and therefore, no interim impairment assessment was performed. Second Quarter Developments During the second quarter of 2022, Teva completed its long-range planning (“LRP”) process. The LRP is part of Teva’s internal financial planning and budgeting processes and is discussed and reviewed by Teva’s management and its board of directors. Additionally, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. Teva identified an increase in certain components of the discount rate, mainly attributable to: (i) the risk free interest rate, which resulted in an increase in the WACC; and (ii) the risk associated with country-specific characteristics of several countries. Based on this quantitative analysis, in the second quarter of 2022, Teva recorded a goodwill impairment charge of $745 million as follows: (i) $479 million related to its International Markets reporting unit, mainly due to the increase in the discount rate; and (ii) $266 million related to its Teva’s API reporting unit, mainly due to the increase in the discount rate, as well as updated assumptions supporting the cash flow projections, including certain revenue growth assumptions and the associated operating profit margins. Following the goodwill impairment charges recorded in relation to Teva’s International Markets and Teva’s API reporting units, the carrying values of those reporting units equaled their fair value as of June 30, 2022. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva’s International Markets or Teva’s API reporting units in the future (see ‘Fourth Quarter Developments’ below). The estimated fair value of Teva’s Europe reporting unit exceeded its estimated carrying amount by 9% based on a terminal growth rate of 1.41% and a discount rate of 10.04%. If Teva held all other assumptions constant, a reduction in the terminal growth rate of 0.50% to 0.91% or an increase in the discount rate of 0.50% to 10.54% would have resulted in a reduction of the excess of fair value over carrying amount with respect to Teva’s Europe reporting unit, as of June 30, 2022, to 5%. Teva’s North America and Medis reporting units had a fair value in excess of 10% over their book values as of June 30, 2022. Teva noted, as of June 30, 2022, that its market capitalization was below management’s assessment of the aggregated fair value of the Company’s reporting units. However, as of that date the Company’s market capitalization plus a reasonable control premium exceeded its book value. Third Quarter Developments During the third quarter of 2022, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of September 30, 2022. Management concluded that no triggering event had occurred and therefore, no interim impairment assessment was performed. Fourth Quarter Developments During the fourth quarter of 2022, Teva completed its annual operating plan (“AOP”) process. The AOP was used as a base for an update of the LRP, incorporating the changes for future years in the fair value model. Additionally, management evaluated whether there were any developments that occurred during the quarter to determine if it is more likely than not that the fair value of any of its reporting units was below its carrying amount as of December 31, 2022. Management noted the following main triggering events during the fourth quarter for its International Markets reporting unit and its Teva’s API reporting unit: (i) fluctuations in exchange rates between certain currencies in which Teva operates in its International Markets reporting unit, and the U.S. dollar, are expected to significantly lower projected operating results; and (ii) updated assumptions supporting the cash flow projections of Teva’s API reporting unit, including certain revenue growth assumptions, and the associated operating profit margins, mainly due to slower-than-expected recovery from the impact of the COVID-19 Management performed a quantitative assessment in the fourth quarter of 2022, which resulted in the recording of a goodwill impairment charge of $500 million related to its International Markets reporting unit and $800 million related to its Teva’s API reporting unit. Following the goodwill impairment charges recorded in relation to Teva’s International Markets and Teva’s API reporting units, the carrying values of those reporting units equaled their fair value as of December 31, 2022. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva’s International Markets or Teva’s API reporting units in the future. With respect to the remaining reporting units, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying amounts as of December 31, 2022 and, therefore, no quantitative assessment was performed.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases	NOTE 8—Leases: The components of operating lease cost for the years ended December 31, 2022, 2021 and 2020 were as follows: Year ended Year ended Year ended 2022 2021 2020 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Operating lease cost: Fixed payments and variable payments that depend on an index or rate $ 142 $ 135 $ 148 Variable lease payments not included in the lease liability 4 4 4 Short-term lease cost 2 2 3 $ 148 $ 141 $ 155 Supplemental cash flow information related to operating leases was as follows: Year ended Year ended Year ended 2022 2021 2020 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 140 $ 143 $ 151 Right-of-use (non-cash): Operating leases $ 81 $ 81 $ 211 Supplemental balance sheet information related to operating leases was as follows: December 31, December 31, 2022 2021 (U.S. $ in millions) (U.S. $ in millions) Operating leases: Operating lease ROU assets $ 419 $ 495 Other current liabilities 93 109 Operating l eas iabilit 349 416 Total operating lease liabilities $ 442 $ 525 December 31, December 31, 2022 2021 Weighted average remaining lease term Operating leases 6.8 years 7.3 years Weighted average discount rate Operating leases 5.6 % 5.4 % Maturities of operating lease liabilities were as follows: December 31, 2022 (U.S. $ in millions) 202 3 116 202 4 94 202 5 79 202 6 66 202 7 188 Total operating lease payments $ 543 Less: imputed interest 101 Present value of lease liabilities $ 442 In 2020, after obtaining the right to use the building, Teva began transitioning its corporate headquarters to a consolidated site in Tel-Aviv, $ million as operating lease ROU assets and $ million as operating lease liability. As of December 31, 2022, Teva’s total finance lease assets finance lease liabilities

Debt obligations

Debt obligations	12 Months Ended
	Dec. 31, 2022
Debt obligations	NOTE 9—Debt obligations: a. Short-term debt: December 31, Weighted average interest rate as of Maturity 2022 2021 (U.S. $ in millions) Convertible debentures 0.25 % 2026 23 23 Current maturities of long-term liabilities 2,086 1,403 Total short term debt $ 2,109 $ 1,426 Convertible senior debentures The principal amount of Teva’s 0.25% convertible senior debentures due 2026 was $23 million as of December 31, 2022 and December 31, 2021. These convertible senior debentures include a “net share settlement” feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the “net share settlement” feature, exercisable at any time, these convertible senior debentures are classified in the balance sheet under short-term debt. b. Long-term debt: Weighted average Maturity December 31, December 31, % (U.S. $ in millions) Senior notes EUR 1,500 million 1.13 % 2024 670 708 Sustainability-linked senior notes EUR 1,500 million (1)(*) 4.38 % 2030 1,606 1,699 Senior notes EUR 1.25 % 2023 633 670 Sustainability-linked senior notes EUR 1,100 million (2)(*) 3.75 % 2027 1,177 1,246 Senior notes EUR 1,000 million 6.00 % 2025 1,070 1,134 Senior notes EUR 900 million 4.50 % 2025 963 1,020 Senior notes EUR 1.63 % 2028 800 844 Senior notes EUR 700 million (3) 3.25 % 2022 — 307 Senior notes EUR 700 million 1.88 % 2027 748 792 Senior notes USD 3,500 million 3.15 % 2026 3,496 3,496 Senior notes USD 3,000 million 2.80 % 2023 1,453 1,453 Senior notes USD 2,000 million 4.10 % 2046 1,986 1,986 Senior notes USD 1,250 million 6.00 % 2024 1,250 1,250 Senior notes USD 1,250 million 6.75 % 2028 1,250 1,250 Senior notes USD 1,000 million 7.13 % 2025 1,000 1,000 Sustainability-linked senior notes USD 1,000 million (2)(*) 4.75 % 2027 1,000 1,000 Sustainability-linked senior notes USD 1,000 million (1)(*) 5.13 % 2029 1,000 1,000 Senior notes USD 844 million (5) 2.95 % 2022 — 715 Senior notes USD 789 million 6.15 % 2036 783 783 Senior notes CHF 350 million (4) 0.50 % 2022 — 382 Weighted average Maturity December 31, December 31, % (U.S. $ in millions) Senior notes CHF 350 million 1.00 % 2025 382 383 Total senior notes 21,266 23,118 Other long-term debt 1 2 Less current maturities (2,086 ) (1,403 ) Less debt issuance costs (78 ) (100 ) Total senior notes and loans $ 19,103 $ 21,617 (1) If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% (2) If Teva fails to achieve certain sustainability performance targets, a one-time 0.15%-0.45% (3) In April 2022, Teva repaid $296 million of its 3.25% senior notes at maturity. (4) In July 2022, Teva repaid $365 million of its 0.50% senior notes at maturity. (5) In December 2022, Teva repaid $713 million of its 2.95% senior notes at maturity. (*) Interest rate adjustments and a potential one-time Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. Teva’s debt as of December 31, 2022 was effectively denominated in the following currencies: U.S. dollar %, euro % and Swiss franc %. Teva’s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $1.8 billion unsecured syndicated sustainability-linked revolving credit facility entered into in April 2022, which was amended in February 2023 (“RCF”). The RCF has a maturity date of April , with two one-year extension options. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time. In addition, the RCF is linked to two sustainability performance targets: (i) the Company’s S&P ESG Score and (ii) number of new regulatory submissions in low and middle-income countries. The RCF margin may increase or decrease depending on the Company’s sustainability performance. On February 6, 2023, the terms of the RCF were amended to update the Company’s maximum leverage ratio under the RCF for certain periods. Under the terms of the RCF, as amended, the Company’s leverage ratio shall not exceed 4.25x in the fourth quarter of 2022, 4.25x in the first, second and third quarters of 2023, 4.00x in the fourth quarter of 2023, 4.00x in the first, second and third quarters of 2024, and 3.50x in the fourth quarter of 2024 and onwards. The RCF can be used for general corporate purposes, including repaying existing debt. As of December 31, 2022 and as of the date of this Annual Report on Form 10-K, amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. Under specified circumstances, including non-compliance Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that these financial statements are issued. As of December 31, 2022, the required annual principal payments of long-term debt (excluding debt discount and issuance costs and fair value hedge adjustments), including convertible senior debentures, starting from the year 2024, are as follows: December 31, (U.S. $ in millions) 2024 $ 1,921 2025 3,412 2026 * 3,523 2027 2,927 2028 and thereafter 7,448 $ 19,231 * I

Derivative instruments and hedg

Derivative instruments and hedging activities	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities	NOTE 10—Derivative instruments and hedging activities: a. Foreign exchange risk management: In , approximately % of Teva’s revenues were denominated i n currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. The Company enters into forward exchange contracts and purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: euro, Swiss franc, Japanese yen, British pound, Canadian dollar, Polish zloty, new Israeli shekel, Indian rupee and other currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (“net investment hedge”) and entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure. Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. b. Interest risk management: The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans, convertible debentures and unsecured syndicated revolving credit facility that bear a fixed or variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (“fair value hedge”) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (“cash flow hedge”), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. c. Bifurcated embedded derivatives: Upon issuance of sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential one-time low-to-middle-income d. Derivative instrument outstanding: The following table summarizes the classification and fair values of derivative instruments: Fair value Not designated as hedging instruments December 31, 2022 December 31, 2021 Reported under (U.S. $ in millions) Asset derivatives: Other current assets: Option and forward contracts $ 29 $ 30 Liability derivatives: Other current liabilities: Option and forward contracts $ (101 ) $ (23 ) The table below provides information regarding the location and amount of pre-tax Reported under Financial expenses, net Other comprehensive income (loss) Year ended December 31, Year ended December 31, 2022 2021 2020 2022 2021 2020 (U.S. $ in millions) Line items in which effects of hedges are recorded $ 966 $ 1,058 $ 834 $ (270 ) $ (391 ) $ (30 ) Cross-currency swaps—net investment hedge (1) — — (2 ) — — (21 ) The table below provides information regarding the location and amount of pre-tax Financial expenses, net Net revenues Year ended December 31, Year ended December 31, 2022 2021 2020 2022 2021 2020 Reported under (U.S. $ in millions) Line items in which effects of hedges are recorded $ 966 $ 1,058 $ 834 $ (14,925 ) $ (15,878 ) $ (16,659 ) Option and forward contracts ( 2 (12 ) (45 ) 130 — — — Option and forward contracts ( 3 — — — (11 ) (31 ) * * Represents an amount less than $0.5 million. (1) In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva’s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float (2) Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. (3) Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Canadian dollar, Polish zloty and some other currencies to protect its projected operating results for 2022 and 2023. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the b revenues e. Amortizations due to terminated derivative instruments: Forward starting interest rate swaps and treasury lock agreements In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position With respect to these forward starting interest rate swaps and treasury lock agreements, losses of $30 million, $37 million and $31 million were recognized under financial expenses, net for the years ended December 31, 2022, 2021 and 2020, respectively. Fair value hedge In the third quarter of 2016, Teva terminated interest rate swap agreements designated as a fair value hedge relating to its 2.95% senior notes due 2022 with respect to $844 million notional amount and its 3.65% senior notes due 2021 with respect to $450 million notional amount. Settlement of these transactions resulted in a gain position of $41 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. In the third quarter of 2019, Teva terminated $500 million interest rate swap agreements designated as a fair value hedge relating to its 2.8% senior notes due 2023 with respect to $3,000 million notional amount. Settlement of these transactions resulted in cash proceeds of $10 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt. Cash flow hedge In the fourth quarter of 2019, Teva terminated $588 million cross-currency swap agreements against its outstanding 3.65% senior notes which were repaid in November 2021. Settlement of these transactions resulted in cash proceeds of $95 million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, were amortized under financial expenses, net over the life of the debt. With respect to the interest rate swap and cross-currency swap agreements, gains of $4 million, $5 million and $3 million were recognized under financial expenses, net for the years ended December 31, 2022, 2021 and 2020, respectively. f. Securitization: U.S. securitization program On November 7, 2022, Teva and a bankruptcy-remote special purpose vehicle (“SPV”) entered into an accounts receivable securitization facility (“AR Facility”) with PNC Bank, National Association (“PNC”) with a three-year term. The AR Facility provides for purchases of accounts receivable by PNC in an amount of up to $1 billion through November 2023, and up to $500 million from November 2023 through November 2025, provided that the SPV may increase the commitment amount up to billion if additional credit providers participate in the AR facility. Under the AR Facility, Teva’s subsidiaries continuously sell their accounts receivables, originated in the U.S., to the SPV and the SPV on-sells The SPV is a variable interest entity (“VIE”) for which Teva is considered to be the primary beneficiary. The SPV’s sole business consists of the purchase of receivables from Teva’s subsidiaries and the subsequent transfer of such receivables to PNC. Although the SPV is included in Teva’s consolidated financial statements, it is a separate legal entity with separate creditors. The assets of the SPV are not available to pay creditors of Teva or its subsidiaries. Upon the transfer of ownership and control of the receivables to the SPV, Teva and its subsidiaries have no retained interests in the receivables sold, and they become unavailable to Teva’s creditors should the relevant seller become insolvent. Teva has collection and administrative responsibilities for the receivables sold to the SPV. The fair value of these servicing arrangements as well as the fees earned was immaterial. The Company accounts for receivables sold from the SPV to PNC as a sale of financial assets under ASC 860 and derecognizes the trade receivables from the Company’s Consolidated Balance Sheet. The total balance of accounts receivables sold to PNC as of December 31, 2022 was $820 million which were derecognized by the SPV. In addition to the accounts receivables sold, an amount of $436 million of the SPV’s accounts receivables is pledged to PNC by the SPV as a seller guarantee, and is included under “Accounts receivables, net”, in the Consolidated Balance Sheet. In the fourth quarter of 2022, Teva received proceeds of $820 million under the AR facility, which are included in cash from operating activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2022. EU securitization program In April 2011, Teva established a trade receivables securitization program (the “EU securitization program”) to sell accounts receivables, mainly originated in Europe, to BNP Paribas Bank (“BNP”). Under the EU securitization program, Teva, on a consolidated basis through its participating subsidiaries, receives an initial cash purchase price and the right to a deferred purchase price (“DPP”), according to the purchase price for the receivables sold by it. On an individual seller basis, each Teva subsidiary participating in the EU securitization program sells receivables to BNP at their nominal amount. BNP then immediately on-sells The SPE is a VIE for which Teva is considered to be the primary beneficiary. The SPE’s sole business consists of the purchase of receivables from Teva subsidiaries and the subsequent sale of such receivables to the conduit. Although the SPE is included in Teva’s consolidated financial statements, it is a separate legal entity with separate creditors. The conduit and other designated creditors of the SPE are entitled, both before and upon the SPE’s liquidation, to be paid out of the SPE’s assets prior to the DPP payable to Teva. The SPE’s assets are not available to pay Teva’s or its subsidiaries’ creditors. In August 2021, Teva extended the EU securitization program by an additional five years, to August 2026. Once a Teva subsidiary sells receivables to BNP, such subsidiary does not retain any interests in the receivables sold and does not have access to such receivables upon its insolvency. The conduit has all the rights in the securitized trade receivables, including the right to pledge or dispose such receivables. Consequently, receivables sold under this agreement are de-recognized The portion of the purchase price for the receivables which is not paid in cash by the conduit is a DPP asset. The conduit pays the SPE the DPP from collections received by the conduit from the securitized trade receivables (after paying senior costs and expenses, including the conduit’s debt service obligations), which the SPE then pays to Teva. The DPP asset represents a beneficial interest in the transferred financial assets and is recognized at fair value as part of the sale transaction. The DPP asset is included in other current assets on Teva’s Consolidated Balance Sheet. Teva has collection and administrative responsibilities for the sold receivables. The fair value of these servicing arrangements as well as the fees earned was immaterial. The DPP asset as of December 31, 2022 and 2021 was $ million and $ million, respectively. As of December 31, 2022 and 2021, the outstanding principal amount of receivables sold, net of DPP, was $636 million and $685 million, respectively. The following table summarizes the change in the sold receivables outstanding balance, net of DPP, under the outstanding securitization program: As of and for the year ended 2022 2021 (U.S. $ in millions) Sold receivables at the beginning of the year $ 685 $ 734 Proceeds from sale of receivables 4,653 5,139 Cash collections (remitted to the owner of the receivables) (4,665 ) (5,152 ) Effect of currency exchange rate changes (37 ) (36 ) Sold receivables at the end of the year $ 636 $ 685

Legal Settlements and Loss Cont

Legal Settlements and Loss Contingencies	12 Months Ended
	Dec. 31, 2022
Legal Settlements and Loss Contingencies	NOTE 11—Legal settlements and loss contingencies: Legal settlements and loss contingencies in 2022 were expenses of $ million, compared to expenses of $ million in 2021 and expense s of $ million in 2020. The expenses in 2022 were mainly related to update s of the estimated settlement provision recorded in connection with the remaining opioid cases. Legal settlements and loss contingencies in 2021 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, the provision for the carvedilol patent litigation as well as a liability which was substantially offset by insurance receivable related to the Ontario Teachers Securities Litigation discussed in note 12b. Legal settlements and loss contingencies in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). As of December 31, 2022 and 2021, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $ million and $ million, respectively. In connection with Teva’s provision for legal settlements and loss contingencies as of D cember 31, 2021 related to the Ontario Teachers Securities Litigation, Teva also recognized an insurance receivable as mentioned above.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and contingencies	NOTE 12—Commitments and contingencies: a. Commitments: Royalty commitments: The Company is committed to pay royalties to owners of know-how, Royalty expenses in each of the years ended December 31, 2022, 2021 and 2020 were $560 million, $522 million and $505 million, respectively. Milestone commitments: Teva has committed to make potential future milestone payments to third parties under various agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, Teva may be required to pay such amounts. As of December 31, 2022, if all development milestones and targets, for compounds in phase 2 and more advanced stages of development, are achieved, the total contingent payments could reach an aggregate amount of up to $26 million. Additional contingent payments are owed upon achievement of product approval or launch milestones. b. Contingencies: General From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is reasonably estimable. Based upon the status of the cases described below, management’s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management’s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva’s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA data. Intellectual Property Litigation From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator’s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the “patent dance” procedures of the Biologics Price Competition and Innovation Act (BPCIA), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator’s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Teva’s pharmaceutical products, not just its generic and biosimilar products. The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva’s product. The amount of lost profits would generally be based on the lost sales of the patentee’s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. In July 2014, GlaxoSmithKline (“GSK”) sued Teva in the District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK’s Coreg ® pre- two-to-one on July 11, 2022. In response to Teva’s certiorari In October 2016, Adapt and Emergent Biosciences Inc. (“EBSI”) sued Teva in the District Court for the District of New Jersey, asserting infringement of its patents expiring in 2035, as a result of Teva’s filing of its Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Narcan ® ® Product Liability Litigation Teva’s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in all of its markets. Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (“API”) supplied to Teva by multiple API manufacturers. Teva’s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (“MDL”) pending in the United States District Courts against Teva and numerous other manufacturers. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. Teva is not named in complaints with respect to irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring class claims. The judge in the valsartan MDL has indicated that the first trial, likely commencing in 2023, will consider third-party payor economic loss claims against Teva and two other defendants . On February 8, 2023 the district court in the valsartan MDL entered an order that certified a series of subclasses on plaintiffs’ economic loss claims and granted in part and denied in part the certification of a medical monitoring class. In the ranitidine MDL, the generics manufacturers’ motions to dismiss have been granted, although certain plaintiffs have appeals pending. In addition, on December 6, 2022, the court in the ranitidine MDL granted the brand defendants’ motions to exclude all of plaintiffs’ general causation experts and granted summary judgment to the brand defendants on that ground. Teva, as well as other generic manufacturers, is also named in several state court actions asserting allegations similar to those in the ranitidine MDL and the valsartan and losartan MDL. State court valsartan and losartan actions are pending in New Jersey and Delaware and are currently stayed. State court ranitidine cases naming Teva are pending in California, Illinois, Pennsylvania, New York and Ohio, with coordinated proceedings in California, Illinois and Pennsylvania. In addition to these MDLs, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva’s, as well as other generic manufacturers’ metformin products. Defendants’ motion to dismiss the plaintiffs’ amended metformin complaint from June 2021 was granted without prejudice with respect to the consumer economic loss plaintiffs and granted in part and denied in part with respect to the end payor plaintiffs. Plaintiffs were granted leave to file a second amended complaint, which defendants have moved to dismiss. Those motions are currently pending. Similar lawsuits are pending in Canada and Germany. Competition Matters As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva’s patent challenges have resulted in litigation relating to Teva’s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i) Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii) significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneys’ fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial—potentially measured in multiples of the annual brand sales—particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva’s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (“FTC”) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test has resulted in increased scrutiny of Teva’s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva’s currently pending antitrust litigations. In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro 60.5 million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. The hearing for the appeal took place in December 2022 and a decision is pending. In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended release venlafaxine (generic Effexor XR ® ® $ billion at the time of settlement and at the time Teva launched its generic version of Effexor XR ® in July 2010. In February 2012, two purported classes of direct-purchaser plaintiffs sued GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal ® ® $ 950 million at the time of the settlement and approximately $2.3 billion at the time Teva launched its generic version of Lamictal ® In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan ® opt-out ® ® Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of end-payers ® end-payers’ ® respectively. At the time Teva launched its authorized generic version of Actos ® 2012, annual sales of Actos ® Putative classes of direct-purchaser and end-payer ® ® ® In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia naming Teva and its affiliates as defendants alleging that certain patent litigation settlement agreements relating to AndroGel ® ® ® Between September 1, 2020 and December 20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and opt-out ® ® ® In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV. Between September and December 2021, several private plaintiffs including retailers and health insurance providers filed similar claims in federal court in the Northern District of California and in the District of Minnesota. As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and 2014 to resolve patent litigation relating to Teva’s generic versions of Viread ® ® ® ® for summary judgment. Trial is currently scheduled to commence in late May 2023. Teva’s motion to dismiss the complaint brought by the State of New Mexico was denied by the trial court on December 2021, but the trial court certified that decision as appropriate for interlocutory appeal. On April 8, 2022, the appellate court in New Mexico declined to accept the appeal, but on October 31, 2022, the New Mexico Supreme Court granted Teva’s petition for a writ of certiorari ® ® ® $ million, $ billion, and $ billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Viread ® ® ® million, $ billion and $ 444 million , respectively. In March 2021, following the 2019 European Commission’s inspection of Teva and subsequent request for information, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. On October 10, 2022, the European Commission issued a Statement of Objections, which sets forth its preliminary allegations that Teva had engaged in anti-competitive practices. Teva now has the opportunity to formally respond to the European Commission’s allegations. Annual sales of COPAXONE in the European Economic Area for 2021 were approximately $373 million. On July 15, 2021, the U.K. Competition and Markets Authority (“CMA”) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK and Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA’s three prior investigations into the supply of hydrocortisone tablets in the U.K., as well as the CMA’s subsequent investigation relating to an anti-competitive agreement with Waymade. On January 9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to two of the three statements of objection from the CMA (dated December 16, 2016 and March 3, 2017), and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October 6, 2021, Accord UK and Auden Mckenzie appealed the CMA’s decision. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. The hearing for the appeal began in December 2022 and is expected to be completed by the end of the first quarter of 2023. In August 2021, a plaintiff filed a putative class action suit in the United States District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys ® filed its amended complaint, making substantively the same antitrust allegations as before, but with certain new allegations regarding the nature of the alleged conspiracy. On March 30, 2022, the Court granted in part and denied in part defendants’ motion to dismiss, dismissing the newly pled bilateral conspiracy claims but allowing the revised overarching conspiracy claim to proceed against all defendants. On April 8, 2022, Teva and Watson, along with their codefendant Amneal, moved the court to reconsider its partial motion to dismiss denial or, in the alternative, to certify that denial for immediate appellate review, but that motion was denied on April 25, 2022. On November 23, 2022, the court denied plaintiffs’ motion for class certification without prejudice, and plaintiffs filed their amended class certification motion on December 22, 2022. The case is still in discovery. Annual sales of Colcrys ® In November 2022, two complaints, one brought by Walgreen Co. and Kroger Specialty Pharmacy, Inc. and another by Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund and Jacksonville Police Officers and Fire Fighters Health Insurance Trust (collectively the “Walgreen and EPP complaints”), were filed in the United States District Court for the District of New Jersey against Teva and its marketing partner, Natco Pharma Limited, alleging violations of the antitrust laws in connection with their December 2015 settlement of patent litigation with Celgene Corporation (which was subsequently acquired by Bristol-Myers Squibb Company (“BMS”)) involving the drug Revlimid ® (lenalidomide). The Walgreen and EPP complaints also name Celgene and BMS as defendants. Teva expects to move to dismiss the complaints. Annual sales of Revlimid ® in the United States were approximately $ billion at the time of the settlement. On December 2, 2022, plaintiffs purporting to represent putative classes of indirect purchasers of EpiPen ® ® ® ® ® ® Government Investigations and Litigation Relating to Pricing and Marketing Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (“DOJ”) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August 25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three-count indictment charging Teva USA with criminal felony Sherman Act violations. See No. 20-cr-200 E-Cream, co-defendant In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January 1, 2009 relevant to the Civil Division’s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December 15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June 18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May 10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November 1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June 10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA, in a similar complaint relating to dermatological generics products. On September 9, 2021, the states’ attorneys general amended their third complaint to, among other things, add California as a plaintiff. In the various complaints described above, the states seek a finding that the defendants’ actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (“Pennsylvania MDL”). On July 13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys’ general November 1, 2019 amended complaint, referenced above, along with certain complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. On February 9, 2021, Teva’s motion to reconsider that ruling was granted, and on May 7, 2021, the Court chose the attorneys’ general third complaint filed on June 10, 2020 and subsequently amended to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. On December 9, 2021, the Court entered an order setting the schedule for the proceedings in the bellwether cases, which the Court later amended on October 13, 2022. This amended schedule does not include trial dates, but provides for the parties to complete briefing on motions for summary judgment in the third quarter of 2024. On June 7, 2022, the Court dismissed the attorneys’ general claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law. Teva has settled with the states of Mississippi (in June 2021), Louisiana (in March 2022), Georgia (in September 2022), Arkansas (in October 2022) and Florida (in February 2023). Teva paid each state an amount proportional to its share of the national population (approximately % share of the national population), and the states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to these settlements. On March 30, 2022, the State of Alabama voluntarily dismissed all of its claims in the litigation, including its claims against Actavis and Teva USA, without prejudice. The most recent settlements with Georgia and Arkansas follow the pattern reached in earlier settlements. Specifically, as mentioned above, Teva agreed to pay each state an amount proportional to its share of the national population. This, in addition to the status of ongoing negotiations with several other U.S. state attorneys general to settle on comparable terms, caused management to consider settlement of the claims filed by the remaining attorneys general to be probable, and management recorded an estimated provision in the third quarter of 2022, in accordance with Accounting Standards Codification 450 “Accounting for Contingencies.” Beginning on March 2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser opt-out In March 2017, Teva received a subpoena from the U.S. Attorney’s office in Boston, Massachusetts requesting documents related to Teva’s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney’s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law (the “DOJ PAP Complaint”). It is alleged that Teva caused the submission of false claims to Medicare through Teva’s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On September 10, 2021, the Court granted Teva’s motion to dismiss the unjust enrichment claim and denied the remainder of the motion. On October 15, 2021, Teva filed an answer to the DOJ PAP Complaint. Trial for this matter is currently scheduled for September 2023. Additionally, on January 8, 2021, Humana, Inc. filed an action against Teva in the United States District Court for the Middle District of Florida based on the allegations raised in the DOJ PAP Complaint. On April 2, 2021, Teva filed a motion to dismiss Humana’s claims on the grounds that the claims are time-barred and/or insufficiently pled, and that motion remains pending and discovery is ongoing. On November 17, 2022, United Healthcare also filed an action against Teva in the United States District Court for the District of New Jersey based on the conduct alleged in the DOJ PAP Complaint. In April 2021, a city and county in Washington sued Teva in the United States District Court for the Western District of Washington for alleged violations of the Racketeer Influenced and Corrupt Organizations Act, Washington’s Consumer Protection Act, and unjust enrichment concerning Teva’s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On September 28, 2021, plaintiffs filed an amended complaint. On November 17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs’ claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. That motion is fully briefed and a decision remains pending. On June 29, 2021, Mylan Pharmaceuticals (“Mylan”) sued Teva in the District Court for the District of New Jersey. On March 11, 2022 and March 15, 2022, FWK Holdings, LLC, KPH Healthcare Servs., Inc. d/b/a Kinney Drugs, Inc., Meijer Inc., Meijer Distribution, Inc., Labor-Management Healthcare Fund, the Mayor and City Council of Baltimore, and the New York State Teamsters Council Health and Hospital Fund sued Teva in the District Court for the District of New Jersey on behalf of themselves and other similarly situated direct and indirect purchasers of COPAXONE. On August 22, 2022, Blue Cross Blue Shield of Vermont and the Vermont Health Plan sued Teva in the District Court for the District of Vermont on behalf of themselves and other similarly situated indirect purchasers of COPAXONE. The complaints assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the RICO Act. Additionally, plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treb

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2022
Income taxes	NOTE 13—Income taxes: a. Income (loss) before income taxes: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Parent Company and its Israeli subsidiaries $ (119 ) $ 126 $ 947 Non-Israeli (2,946 ) 532 (5,353 ) $ (3,065 ) $ 658 $ (4,406 ) b. Income taxes: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) In Israel $ 33 $ 124 $ 60 Outside Israel (671 ) 87 (228 ) $ (638 ) $ 211 $ (168 ) Current $ 430 $ 270 $ 182 Deferred (1,068 ) (59 ) (350 ) $ ) $ 211 $ (168 ) Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Income (loss) before income taxes $ (3,065) $ 658 $ (4,406) Statutory tax rate in Israel 23% 23% 23% Theoretical provision for income taxes $ (705) $ 151 $ (1,013) Increase (decrease) in the provision for income taxes due to: The Parent Company and its Israeli subsidiaries - Tax benefits arising from reduced tax rates under benefit programs 15 (12) (153) Mainly nondeductible items and prior year tax 35 20 (30) Non-Israeli 924 117 1,369 Worthless stock deduction (**) (909) — — Increase (decrease) in other uncertain tax positions—net 2 (65) (341) Effective consolidated income taxes $ (638) $ 211 $ (168) * In 2022 and 2020, loss non-Israeli ** In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva will recognize on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million. The effective tax rate is the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to non-Israeli In 2020, Teva released a valuation allowance on its deferred tax assets in one jurisdiction and recorded a valuation allowance in another jurisdiction, with both adjustments reflecting changes in the business forecasts of profitability in these jurisdictions. The net effect of these changes did not materially impact Teva’s effective tax rate for 2020. c. Deferred income taxes: December 31, 2022 2021 (U.S. $ in millions) Deferred tax assets (liabilities), net: Inventory related $ 125 $ 104 Sales reserves and allowances 89 136 Provision for legal settlements 703 360 Intangible assets (*) (567 ) (814 ) Carryforward losses and deductions and credits (**) 2,850 2,093 Property, plant and equipment (238 ) (215 ) Deferred interest 800 617 Provisions for employee related obligations 82 95 Other 133 159 3,977 2,535 Valuation allowance—in respect of carryforward losses and deductions that may not be (3,072 ) (2,723 ) $ 905 $ (188 ) (*) The decrease in deferred tax liability is mainly due to impairment and amortization. (**) The amounts are shown following a reduction for unrecognized tax benefits of $1 million and $10 million as of December 31, 2022 and 2021, respectively. The amount as of December 31, 2022 represents the tax effect of gross carryforward losses and deductions with the following expirations: 2023 - 2024 — $ million; 2025 - 2032 — $ million; 2033 and thereafter — $ million. The remaining balance—$ million—can be utilized with no expiration date. The deferred income taxes are reflected in the balance sheet among: December 31, 2022 2021 (U.S. $ in millions) Long-term assets—deferred income taxes 1,453 596 Long-term liabilities—deferred income taxes (548 ) (784 ) $ 905 $ (188 ) d. Uncertain tax positions: The following table summarizes the activity of Teva’s gross unrecognized tax benefits: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Balance at the beginning of the year $ 672 $ 888 $ 1,223 Increase (decrease) related to prior year tax positions, net (46 ) (106 ) (238 ) Increase related to current year tax positions 42 7 10 Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations (31 ) (115 ) (105 ) Other 1 (2 ) (2 ) Balance at the end of the year $ 638 $ 672 $ 888 Uncertain tax positions, mainly of a long-term nature, include accrued potential penalties and interest of $212 million, and million and $9 million for the years ended December 31, 2022, 2021 and 2020, respectively. Substantially all the above uncertain tax benefits, if recognized, would reduce Teva’s annual effective tax rate. Teva does not expect uncertain tax positions to change significantly over the next 12 months, except in the case of settlements with tax authorities or court decisions, the likelihood and timing of which is difficult to estimate. e. Tax assessments: Teva files income tax returns in various jurisdictions with varying statutes of limitations. Teva and its subsidiaries in Israel have received final tax assessments through tax year 2011. The Israeli tax authorities (“ITA”) issued tax assessment decrees for 2008-2011, 2012 and 2013-2016, challenging the Company’s positions on several issues. Teva has protested the 2008-2011, 2012 and 2013-2016 decrees before the Central District Court in Israel. In October 2021, the Central District Court in Israel held in favor of the Israeli tax authorities with respect to 2008-2011 decrees. The case with respect to 2012-2016 remains pending with similar legal and other claims. Teva appealed this decision to the Israeli Supreme Court and expects the appeal hearing to begin in the second half of 2023. The tax liability resulting from the October 2021 Central District Court decision, with respect to the decrees for 2008-2011 and with regard to the similar legal claims in the related following years, was approximately $ 350 million, of which a portion has been and will continue to be paid during 2022 and 2023. The Company believes it has adequately provided for all of its uncertain tax positions, including those items currently under dispute, however, adverse results could be material. In the United States, Teva has one tax issue in dispute for the 2009-2011 audit cycle, which is currently in litigation. The 2012-2014 audit cycle is complete with the exception of the same issue, which is currently on hold pending the outcome of the earlier case. Teva has current ongoing U.S. federal income tax audits for its U.S. subsidiaries for years 2015-2019. Additionally, Teva’s U.S. subsidiaries have multiple state audit cycles open ranging from years 2013-2020. The Company believes it has adequately provided for these items and that any adverse results would have an immaterial impact on Teva’s financial statements. Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is ongoing. A final and binding decision against Teva in this case may lead to an impairment in the amount of $ 127 million. The Company’s subsidiaries in Europe have received final tax assessments mainly through tax year 2015. f. Basis of taxation: The Company and its subsidiaries are subject to tax in many jurisdictions, and estimation is required in recording the assets and liabilities related to income taxes. The Company believes that its accruals for tax liabilities are adequate for all open years. The Company considers various factors in making these assessments, including past history, recent interpretations of tax law, and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these assessments can involve a series of complex judgments regarding future events. An assessment of the tax that would have been payable had the Company’s foreign subsidiaries distributed their income to the Company is not practicable because of the multiple levels of corporate ownership and multiple tax jurisdictions involved in each hypothetical dividend distribution. Incentives Applicable until 2013 Under the incentives regime applicable to the Company until 2013, industrial projects of Teva and certain of its Israeli subsidiaries were eligible for “Approved Enterprise” status. Most of the projects in Israel have been granted Approved Enterprise status under the “alternative” tax benefit track which offered tax exemption on undistributed income for a period of two to ten years, depending on the location of the enterprise. Upon distribution of such exempt income, the distributing company is subject to corporate tax at the rate ordinarily applicable to the Approved Enterprise’s income. Amendment 69 to the Investment Law Pursuant to Amendment 69 to the Investment Law (“Amendment 69”), a company that elected by November 11, 2013 to pay a corporate tax rate as set forth in that amendment (rather than the tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company up until December 31, 2011 is entitled to distribute a dividend from such income without being required to pay additional corporate tax with respect to such dividend. A company that has so elected must make certain qualified investments in Israel over the five-year period commencing in 2013. Teva invested the entire required amount in 2013. During 2013, Teva applied the provisions of Amendment 69 to certain exempt profits Teva accrued prior to 2012. Consequently, Teva paid $577 million in corporate tax on exempt income of $9.4 billion. Part of this income was distributed as dividends during 2013-2018, while the remainder is available to be distributed as dividends in future years with no additional corporate tax liability. Incentives Applicable starting 2014 : The Incentives Regime – Amendment 68 to the Investment Law Under Amendment 68 to the Investment Law, which Teva started applying in 2014, upon an irrevocable election made by a company, a uniform corporate tax rate will apply to all qualifying industrial income of such company (“Preferred Enterprise”), as opposed to the previous law’s incentives, which were limited to income from Approved Enterprises during the benefits period. Under the law, when the election is made, the uniform tax rate for 2014 until 2016 was 9% in areas in Israel designated as Development Zone A and 16% elsewhere in Israel. The uniform tax rate for Development Zone A, as of January 1, 2017, is 7.5% (as part of changes enacted in Amendment 73, as described below). The profits of these “Preferred Enterprise” will be freely distributable as dividends, subject to a 20% or lower withholding tax, under an applicable tax treaty. Certain “Special Preferred Enterprises” that meet more stringent criteria (significant investment, R&D or employment thresholds) will enjoy further reduced tax rates of 5% in Zone A and 8% elsewhere. In order to be classified as a “Special Preferred Enterprises,” the approval of three governmental authorities in Israel is required. The New Technological Enterprise Incentives Regime – Amendment 73 to the Investment Law Since 2017, a portion of the Company’s taxable income in Israel is entitled to a preferred 6% tax rate under Amendment 73 to the Investment Law as it pertains to Special Preferred Technological Enterprises. The new incentives regime applies to “Preferred Technological Enterprises” or “Special Preferred Technological Enterprises.” A “Preferred Technological Enterprise” is an enterprise that meet certain conditions, including, inter alia: • Investment of at least 7% of income, or at least NIS 75 million (approximately $22 million) in R&D activities; and • One of the following: a. At least 20% of the workforce (or at least 200 employees) are employed in R&D; b. A venture capital investment approximately equivalent to at least $2 million was previously made in the company; or c. Growth in sales or workforce by an average of 25% over the three years preceding the tax year. A “Special Preferred Technological Enterprise” is an enterprise that meets, inter alia conditions 1 and 2 above, and in addition has total annual consolidated revenues above NIS 10 billion (approximately $2.9 billion). Preferred Technological Enterprises are subject to a corporate tax rate of 7.5% on their income derived from intellectual property in areas in Israel designated as Zone A and 12% elsewhere, while Special Preferred Technological Enterprises are subject to 6% on such income. The withholding tax on dividends from these enterprises is 4% to foreign companies (or a lower rate under a tax treaty, if applicable). Income not eligible for Preferred Technological Enterprise benefits is taxed at the regular corporate tax rate, which is 23%, or the preferred tax rate, as the case may be. The Parent Company and its Israeli subsidiaries elected to compute their taxable income in accordance with Income Tax Regulations (Rules for Accounting for Foreign Investors Companies and Certain Partnerships and Setting their Taxable Income), 1986. Accordingly, the taxable income or loss is calculated in U.S. dollars. Applying these regulations reduces the effect of U.S. dollar – NIS exchange rate on the Company’s Israeli taxable income. Non-Israeli deductions. The 2021 Budget Law On November 15, 2021, the Israeli Parliament released its 2021-2022 Budget Law (“2021 Budget Law”). The 2021 Budget Law introduces a new dividend ordering rule that apportions every dividend between previously tax-exempt tax-exempt tax-exempt

Equity

Equity	12 Months Ended
	Dec. 31, 2022
Equity	NOTE 14—Equity: a. Ordinary shares and ADSs As of December 31, 2022 and 2021, Teva had approximately 1.2 billion ordinary shares issued. Teva ordinary shares are traded on the Tel-Aviv b. Stock-based compensation plans Stock-based compensation plans are comprised of stock options, RSUs, PSUs, and other equity-based awards to employees, officers, directors and consultants of the Company and its affiliates. The purpose of the plans is to (a) attract, retain, motivate, and reward such individuals, and (b) promote the creation of long-term value for shareholders of the Company by closely aligning the interests of such individuals with those of the shareholders. On June 29, 2010, the Teva 2010 Long-Term Equity-Based Incentive Plan (“2010 Plan”) was approved by Teva’s shareholders, under which 70 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. The 2010 Plan expired on June 28, 2015 (except with respect to awards outstanding on that date), and no additional awards under the 2010 Plan may be made. On September 3, 2015, the Teva 2015 Long-Term Equity-Based Incentive Plan (“2015 Plan”) was approved by Teva’s shareholders, under which 43.7 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. On April 18, 2016, Teva’s shareholders approved an increase of an additional 33.3 million equivalent share units to the share reserve of the 2015 Plan, so that 77 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. On July 13, 2017, Teva’s shareholders approved an increase of an additional 65 million equivalent share units to the share reserve of the 2015 Plan, so that 142 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. The 2015 Plan expired on June 30, 2020 (except with respect to awards outstanding on that date), and no additional awards under the 2015 Plan may be made. On June 11, 2020, the Teva 2020 Long-Term Equity-Based Incentive Plan (“2020 Plan”) was approved by Teva’s shareholders and became effective on July 1, 2020. Under the 2020 Plan, 68 million shares, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. As of December 31, 2022, 74.0 In the past, Teva had various employee-stock and incentive plans under which stock options and other share-based awards were granted. Stock options and other share-based awards granted under such prior plans continue in accordance with the terms of the respective plans. The vesting period of the outstanding options and RSUs is generally between 1 to 4 years from date of grant. The vesting period of PSUs is generally 3 years from date of grant. The rights of ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of other ordinary shares of the Company. The contractual term of these options is primarily for ten years. Status of options A summary of the status of the options granted by Teva as of December 31, 2022, 2021 and 2020, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). Year ended December 31, 2022 2021 2020 Number (in thousands) Weighted Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 29,015 $ 36.96 35,234 $ 37.27 40,064 $ 37.90 Changes during the year: Forfeited (2,378 ) 33.77 (3,644 ) 36.09 (3,610 ) 40.24 Expired (2,518 ) 41.26 (2,575 ) 42.40 (1,220 ) 49.35 Balance outstanding at end of year 24,119 36.83 29,015 36.96 35,234 37.27 Balance exercisable at end of year 24,119 36.83 26,989 38.30 28,556 40.56 No options were granted during 2022, 2021 and 2020. The following table summarizes information as of December 31, 2022 regarding the number of ordinary shares issuable upon vested options: Number of ordinary shares issuable upon exercise of vested options Range of exercise prices Balance at end of period (in thousands) Weighted average Weighted average Number of shares $ Years Lower than $15.01 592 11.40 4.84 $15.01 - $25.00 7,781 18.96 5.13 $25.01 - $35.00 5,712 34.61 4.16 $35.01 - $45.00 509 38.13 0.57 $45.01 - $55.00 5,906 51.30 2.36 $55.01 - $65.00 3,619 59.10 2.33 Total 24,119 36.83 3.70 The aggregate intrinsic value represents the total pre-tax represents the potential amount receivable by the option holders had all option holders exercised their options as of such date. As of December 31, 2022, there were no exercisable options that were in-the-money. No options were exercised during 2022, 2021 and 2020. Status of non-vested The following table summarizes information about the number of RSUs and PSUs granted and outstanding: Year ended December 31, 2022 2021 2020 Number (in thousands) Weighted grant date fair value Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 24,412 $ 11.58 20,720 $ 13.81 15,977 $ 16.49 Granted 18,755 7.42 12,748 10.42 10,848 11.42 Vested (7,571 ) 13.02 (6,818 ) 15.60 (4,324 ) 19.49 Forfeited (3,293 ) 9.81 (2,238 ) 12.18 (1,781 ) 18.18 Balance outstanding at end of year 32,302 9.11 24,412 11.58 20,720 13.81 The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2022, 2021 and 2020, the Company recorded stock-based compensation costs as follows: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Employee stock options $ 2 $ 16 $ 30 RSUs and PSUs 122 103 99 Total stock-based compensation expense 124 119 129 Tax effect on stock-based compensation expense 9 12 14 Net effect $ 115 $ 107 $ 115 As of December 31, 2022, the total unrecognized compensation cost before tax on RSUs/PSUs amounted to $181 million. The cost is expected to be recognized over a weighted average period of approximately 2.5 years. There were no unrecognized compensation costs related to employee stock options. c Dividends Teva has not paid dividends on Teva ordinary shares or ADSs since December 2017. d Accumulated other comprehensive loss The components of accumulated other comprehensive loss attributable to Teva are presented in the table below: Net Unrealized Gains/(Losses) Benefit Plans Foreign Derivative Actuarial Total (U.S. $ in millions) Balance as of January 1, 2020 $ (1,794 ) (420 ) (98 ) (2,312 ) Other comprehensive income/(loss) before reclassifications (190 ) 22 (7 ) (175 ) Amounts reclassified to the statements of income — 35 (12 ) 23 Net other comprehensive income/(loss) before tax (190 ) 57 (19 ) (152 ) Corresponding income tax 65 — 1 66 Net other comprehensive income/(loss) after tax* (125 ) 57 (18 ) (86 ) Balance as of December 31, 2020 (1,919 ) (363 ) (117 ) (2,399 ) Other comprehensive income/(loss) before reclassifications (386 ) — 18 (368 ) Amounts reclassified to the statements of income — 39 18 57 Net other comprehensive income/(loss) before tax (386 ) 39 36 (311 ) Corresponding income tax 31 — (4 ) 27 Net other comprehensive income/(loss) after tax* (355 ) 39 32 (284 ) Balance as of December 31, 2021 (2,274 ) (324 ) (85 ) (2,683 ) Other comprehensive income/(loss) before reclassifications (223 ) — 40 (183 ) Amounts reclassified to the statements of income — 29 27 56 Net other comprehensive income/(loss) before tax (223 ) 29 67 (127 ) Corresponding income tax (17 ) — (10 ) (27 ) Net other comprehensive income/(loss) after tax* (240 ) 29 57 (154 ) Balance as of December 31, 2022 $ (2,514 ) $ (295 ) $ (28 ) $ (2,838 ) * Amounts do not include foreign currency translation adjustments attributable to non-controlling

Other assets impairments, restr

Other assets impairments, restructuring and other items	12 Months Ended
	Dec. 31, 2022
Other assets impairments, restructuring and other items	NOTE 15—Other assets impairments, restructuring and other items: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) I mpairmen $ 47 $ 160 $ 416 Contingent consideration (see note 20) 163 7 (81 ) Restructuring 146 133 120 Other 57 41 24 Total $ 414 $ 341 $ 479 (1) Including impairments related to exit and disposal activities. Impairments Impairments of tangible assets for the years ended December 31, 2022, 2021 and 2020 were $47 million, $160 million and $416 million, respectively. The impairment for the year ended December 31, 2022 was mainly related to certain assets in North America. The impairment for the year ended December 31, 2021 was mainly related to certain assets in Europe and North America. The impairment for the year ended December 31, 2020 was mainly related to the sale of certain assets from Teva’s business venture in Japan, which was completed on February 1, 2021, as well as plant rationalization. Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities. Contingent consideration In 2022, Teva recorded an expense of $163 million for contingent consideration, compared to an expense of $7 million in 2021 and an income of $81 million in 2020, respectively. The expense in 2022 was mainly related to changes in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid ® ® Restructuring In 2022, Teva recorded $146 million of restructuring expenses, compared to $133 million in 2021 and $120 million in 2020. The expenses in 2022 were primarily related to network consolidation activities. The expenses in 2021 and 2020 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017. The following tables provide the components of restructurin g costs: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Restructuring Employee termination $ 117 $ 117 $ 71 Other 29 16 49 Total $ 146 $ 133 $ 120 157 The following table provides the components of and changes in the Company’s restructuring accruals: Employee Other Total (U.S. $ in millions ) Balance as of January 1, 2020 $ (208 ) $ (7 ) $ (215 ) Provision (71 ) (49 ) (120 ) Utilization and other* 164 49 213 Balance as of January 1, 2021 $ (115 ) $ (7 ) $ (122 ) Provision (117 ) (16 ) (133 ) Utilization and other* 101 16 117 Balance as of December 31, 2021 $ (131 ) $ (7 ) $ (138 ) Provision (117 ) (29 ) (146 ) Utilization and other* 136 29 165 Balance as of December 31, 2022 $ (112 ) (7 ) (119 ) * Includes adjustments for foreign currency translation. Significant regulatory and other events In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. (“Huahai”). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva’s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs. See note 12b for further discussion. In the second quarter of 2020, Teva’s operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva completed partial remediation of this issue and restarted limited supply from its Goa facilities. The site experienced some additional delays in the first quarter of 2021 due to labor related issues, but the situation stabilized during the second quarter of 2021. The water supply remediation was completed in December 2022, and since then, the site is operating with an upgraded water system. The impact on Teva’s financial results for the year ended December 31, 2022 was immaterial. In June 2021, the Company temporarily paused manufacturing at its Irvine, California facility in the United States, and suspended release of product from the facility pending completion of an open manufacturing investigation. In July 2021, the FDA initiated an establishment inspection at the facility. On August 18, 2021, the Company issued field alert reports to the FDA for products manufactured at the Irvine facility and put Irvine-manufactured products in Teva’s distribution center on hold. On August 20, 2021, the FDA completed its inspection and issued a Form FDA-483 the FDA notified the Company that the inspection classification of this site is “Official Action Indicated” (“OAI”). Teva began working diligently to address the FDA’s concerns in a manner consistent with current good manufacturing practice (“CGMP”) requirements, and was in discussions with the FDA Drug Shortage Staff (“DSS”) and FDA Office of Manufacturing Quality (“OMQ”) to recommence the distribution, release and manufacture of certain medically necessary products from the site under defined controls and protocols. On March 22, 2022, the Company announced its decision to permanently cease all manufacturing activities and to close the site, and to transfer certain products to other facilities. Teva will remain in contact with FDA regarding the status of Irvine, California site to ensure that the Company continues to comply with all relevant CGMP requirements, particularly those involved with product transfers to other sites within the Teva network. Teva has considered these developments and, during the year ended December 31, 2022, recorded $98 million costs in its financial statements related to this matter. In December 2022, Teva sold its Irvine, California site.

Other income

Other income	12 Months Ended
	Dec. 31, 2022
Other income	NOTE 16—Other income: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Gain on divestitures, net of divestitures related costs (1) $ 46 51 8 Section 8 and similar payments (2) 13 19 — Gain (loss) on sale of assets 18 7 11 Other, net (3) 31 22 20 Total other income $ 107 $ 98 $ 40 (1) In 2022, mainly related to the divestment of several activities in North America and International Markets. In 2021, mainly due to capital gains related to the sale of certain OTC assets. In 2020, mainly related to the divestment of several activities in International Markets. (2) Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada. (3) In 2022, mainly the result of settlement proceeds related to the International Markets segment.

Financial expenses, net

Financial expenses, net	12 Months Ended
	Dec. 31, 2022
Financial expenses, net	NOTE 17—Financial expenses, net: Year ended December, 31 2022 2021 2020 (U.S. $ in millions) Interest expenses and other bank charges 930 891 901 (Income) loss from investments (1) (10 ) 90 (104 ) Foreign exchange (gains) losses, net (16 ) 7 (26 ) Other, net (2) 61 71 62 Total finance expense, net $ 966 $ 1,058 $ 834 (1) (Income) loss from investments in 2021 and 2020 comprised mainly of revaluation gains and loss of Teva’s investment in American Well Corporation (“American Well”). (2) Amortization of issuance costs and terminated derivative instruments.

Earnings (Loss) per Share

Earnings (Loss) per Share	12 Months Ended
	Dec. 31, 2022
Earnings (Loss) per Share	NOTE 18—Earnings (loss) per share: The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2022, 2021 and 2020 are as follows: Year ended December, 31 2022 2021 2020 (U.S. $ in millions, except share data) Net income (loss) used for the computation of basic and diluted earnings (loss) per share (2,353 ) $ 417 $ (3,990 ) Weighted average number of shares used in the computation of basic earnings (loss) per share 1,110 1,102 1,095 Weighted average number of shares used in the computation of diluted earnings (loss) per share 1,110 1,107 1,095 Basic earnings (loss) per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested RSUs and PSUs during the period), net of treasury shares. In computing diluted loss per share for the year ended December 31, 2022, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested In computing diluted earnings per share for the year ended December 31, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested In computing diluted loss per share for the year ended December 31, 2020, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested Basic and diluted loss per share was $2.12 for the year ended December 31, 2022, compared to basic and diluted earnings per share of $0.38 for the year ended December 31, 2021 and basic and dilute d 20

Segments

Segments	12 Months Ended
	Dec. 31, 2022
Segments	NOTE 19—Segments: Teva operates its business and reports its financial results in three segments: (a) North America segment, which includes the United States and Canada. (b) Europe segment, which includes the European Union, the United Kingdom and certain other European countries. (c) International Markets segment, which includes all countries other than those in the North America and Europe segments. In addition to these three segments, Teva has other sources of revenues included in other activities, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing Teva’s Chief Executive Officer (“CEO”), who is the chief operating decision maker (“CODM”), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance. Segment profit is comprised of gross profit for the segment less R&D expenses, S&M expenses, G&A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva’s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. Teva’s CEO may review its strategy and organizational structure. Any changes in strategy may lead to a reevaluation of the Company’s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 7. a. Segment information: Year ended December 31, 2022 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,452 $ 4,525 $ 1,903 Gross profit 3,926 2,700 1,033 R&D expenses 532 213 72 S&M expenses 941 748 405 G&A expenses 474 246 119 Other income (15 ) (3 ) (43 ) Segment profit $ 1,993 $ 1,496 $ 479 Year ended December 31, 2021 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,809 $ 4,886 $ 2,032 Gross profit 4,226 2,823 1,118 R&D expenses 618 244 68 S&M expenses 988 846 417 G&A expenses 427 244 109 Other income (31 ) (5 ) (5 ) Segment profit $ 2,224 $ 1,494 $ 529 Year ended December 31, 2020 North America Europe International Markets (U.S. $ in millions) Revenues $ 8,447 $ 4,757 $ 2,154 Gross profit 4,489 2,666 1,096 R&D expenses 622 247 70 S&M expenses 1,013 830 427 G&A expenses 443 261 136 Other income (10 ) (3 ) (11 ) Segment profit $ 2,421 $ 1,331 $ 474 Year ended December 31, 2022 2021 2020 (U.S. $ in millions) North America profit $ 1,993 $ 2,224 $ 2,421 Europe profit 1,496 1,494 1,331 International Markets profit 479 529 474 Total reportable segments profit 3,968 4,246 4,225 Profit of other activities 172 154 163 Total segments profit 4,140 4,401 4,388 Amounts not allocated to segments: Amortization 732 802 1,020 Other assets impairments, restructuring and other items 414 341 479 Goodwill impairment 2,045 — 4,628 Intangible asset impairments 355 424 1,502 Legal settlements and loss contingencies 2,082 717 60 Other unallocated amounts 610 402 271 Consolidated operating income (loss) (2,099 ) 1,716 (3,572 ) Financial expenses, net 966 1,058 834 Consolidated income (loss) before income taxes $ (3,065 ) $ 658 $ (4,406 ) b. Segment revenues by major products and activities: The following tables present revenues by major products and activities for each segment for the year ended December 31, 2022, 2021 and 2020: North America segment: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Generic products $ 3,549 $ 3,769 $ 4,010 AJOVY 218 176 134 AUSTEDO 963 802 637 BENDEKA and TREANDA 316 385 415 COPAXONE 387 577 884 Anda 1,471 1,323 1,462 Other 549 777 905 Total $ 7,452 $ 7,809 $ 8,447 Europe segment: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Generic products $ 3,466 $ 3,569 $ 3,513 AJOVY 124 87 31 COPAXONE 268 391 400 Respiratory products 273 356 353 Other 393 483 459 Total $ 4,525 $ 4,886 $ 4,757 International Markets segment: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Generic products $ 1,586 $ 1,649 $ 1,792 AJOVY 35 50 18 COPAXONE 36 37 53 Other 246 295 291 Total $ 1,903 $ 2,032 $ 2,154 Revenues are attributable to countries based on sales to third parties in such countries. Revenues within the United States constituted 47%, 46% and 48% of Teva’s consolidated revenues for the years ended December 31, 2022, 2021 and 2020, respectively. Revenues within the Company’s country of domicile (Israel) constituted 2%, 2% and 2% of Teva’s consolidated revenues for the years ended December 31, 2022, 2021 and 2020, respectively. c. Supplemental data—major customers: The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2022, 2021 and 2020. Percentage of Third Party Net Sales 2022 2021 2020 McKesson Corporation 10 % 11 % 12 % AmerisourceBergen Corporation 10 % 11 % 12 % Most of Teva’s revenues from these customers were in the North America segment. d. Property, plant and equipment—by geographical location were as follows: December 31, 2022 2021 (U.S. $ in millions) Israel $ 1,401 $ 1,543 Germany 1,143 1,045 United States 625 692 Croatia 445 481 Czech republic 318 324 Hungary 294 321 Ireland 268 269 Other 1,245 1,307 Total property, plant and equipment $ 5,739 $ 5,982

Fair value measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2022
Fair value measurement	NOTE 20—Fair value measurement: Financial items carried at fair value as of December 31, 2022 and 2021 are classified in the tables below in one of the three categories described in note 1f: December 31, 2022 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 1,222 — — $ 1,222 Cash, deposits and other 1,579 — — 1,579 Investment in securities: Equity securities 9 — — 9 Other 5 — 1 6 Restricted cash 33 — — 33 Derivatives: Asset derivatives : O s — 29 — 29 Liabilities derivatives — Options and forward contracts — (101 ) — (101 ) Bifurcated embedded derivatives — — § — Contingent consideration* — — (153 ) (153 ) Total $ 2,848 $ (73 ) $ (152 ) $ 2,624 § Represents an amount less than 0.5 million * Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.. December 31, 2021 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 220 — — $ 220 Cash, deposits and other 1,945 — — 1,945 Investment in securities: Equity securities 18 — — 18 Other 6 — 1 7 Restricted cash 33 — — 33 Derivatives: Asset derivatives: Options and forward contracts — 30 — 30 Liability derivatives: Options and forward contracts — (23 ) — (23 ) Bifurcated embedded derivatives — — § — Contingent consideration* — — (176 ) (176 ) Total $ 2,222 $ 7 $ (175 ) $ 2,054 § Represents an amount less than $0.5 million. * Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor ranging from 90% to 100% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&D. The discount rate applied ranged from 8.5% to 11%. The weighted average discount rate, calculated based on the relative fair value of Teva’s contingent consideration liabilities, was 8.9%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs. December 31, December 31, (U.S. $ in millions) Fair value at the beginning of the period $ (175 ) $ (258 ) Redemption of debt securities — (9 ) Bifurcated embedded derivatives § § Adjustments to provisions for contingent consideration: Actavis Generics transaction (142 ) 15 Eagle transaction (21 ) (23 ) Settlement of contingent consideration: Actavis Generics transaction 109 100 Eagle transaction 88 — Additional contingent consideration resulting from Novetide acquisition* (11 ) — Fair value at the end of the period $ (152 ) $ (175 ) § Represents an amount less than 0.5 million. * In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated companies”. This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under “Share in (profits) losses of associated companies, net”, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. Teva’s financial instruments consist mainly of cash and cash equivalents, investments in securities, current and non-current The fair value of the financial instruments included in working capital and non-current Financial instruments not measured at fair value Financial instruments measured on a basis other than fair value consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value: Estimated fair value* December 31, 2022 2021 (U.S. $ in millions) Senior notes and sustainability-linked senior notes included under senior notes and loans $ 16,694 $ 21,477 Senior notes and convertible senior debentures included under short-term debt 2,075 1,426 Total $ 18,769 $ 22,903 * The fair value was estimated based on quoted market prices.

Long-term Employee-related Obli

Long-term Employee-related Obligations	12 Months Ended
	Dec. 31, 2022
Long-term Employee-related Obligations	NOTE 21—Long-term employee-related obligations: a. Long-term employee-related obligations consisted of the following: December 31, 2022 2021 (U.S. $ in millions) Accrued severance obligations $ 74 $ 83 Defined benefit plans 58 142 Total $ 132 $ 225 As of December 31, 2022 and 2021, Teva had $79 million and $97 million, respectively, deposited in funds managed by financial institutions and earmarked by management to cover severance pay liability. Such deposits are not considered to be “plan assets” and are therefore included in other non-current Most of the change resulted from actuarial updates, as well as from exiting from several defined benefit plans in several countries. The Company expects to expense an approximate contribution of $111 million in 2023 to pension funds and insurance companies in connection with its severance and pension pay obligations. The main terms of the different arrangements with employees are described in below. b. Terms of arrangements: Israel Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Parent Company and its Israeli subsidiaries make ongoing deposits into employee pension plans to fund their severance liabilities. Generally, employees that joined the Company after 2005, have signed an arrangement, pursuant to which such deposits are made in lieu of the Company’s severance liability. Therefore, no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who were employed by the Parent Company and its Israeli subsidiaries prior to that date, as well as employees who have special contractual arrangements, are provided for in the financial statements based upon the number of years of service and the latest monthly salary of such employees. Europe Many of the employees in the Company’s European subsidiaries are entitled to a retirement grant when they leave the Company. In the consolidated financial statements, the liability of the European subsidiaries is accrued, based on the length of service and remuneration of each employee at the balance sheet date. Other employees in Europe are entitled to a pension according to a defined benefit scheme providing benefits based on final or average pensionable pay or according to a hybrid pension scheme that provides retirement benefits on a defined benefit and a defined contribution basis. Independent certified actuaries value these schemes and determine the rates of contribution payable. Pension costs for the defined benefit section of the scheme are accounted for on the basis of charging the expected cost of providing pensions over the period during which the subsidiaries benefit from the employees’ services. The Company uses December 31 as the measurement date for defined benefit plans. North America The Company’s North American subsidiaries mainly provide various defined contribution plans for the benefit of their employees. Under these plans, contributions are based on specified percentages of pay. Additionally, a multi-employer plan is maintained in accordance with various union agreements. Latin America The majority of the employees in Latin America are entitled to severance under local law. The severance payments are calculated based on service term and employee remuneration, and accruals are maintained to reflect these amounts. In some Latin American countries, it is Teva’s practice to offer retirement health benefits to qualifying employees. Based on the specific plan requirements, benefits accruals are maintained to reflect the estimated amounts or adjusted if future plans are modified. The Company expects to pay the following future minimum benefits to its employees: $14 million in 2023; $12 million in 2024; $12 million in 2025; $13 million in 2026; $13 million in 2027;

Schedule of Valuation and Quali

Schedule of Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2022
Schedule of Valuation and Qualifying Accounts	Column A Column B Column C Column D Column E Balance at Charged to costs Charged to other Deductions Balance at end Allowance for doubtful accounts: Year ended December 31, 2022 164 8 (2 ) (8 ) 162 Year ended December 31, 2021 $ 200 $ (8 ) $ — $ (28 ) $ 164 Year ended December 31, 2020 $ 209 $ (11 ) $ 2 $ — $ 200 Allowance in respect of carryforward tax losses and deductions that may not be utilized: Year ended December 31, 2022 $ 2,723 $ 443 $ — $ (93 ) $ 3,072 Year ended December 31, 2021 $ 2,547 $ 336 $ — $ (160 ) $ 2,723 Year ended December 31, 2020 $ 1,974 $ 670 $ — $ (97 ) $ 2,547

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
General	a. General: Operations Teva Pharmaceutical Industries Limited (the “Parent Company”), headquartered in Israel, together with its subsidiaries and associated companies (the “Company,” “Teva” or the “Group”), is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The majority of the Group’s revenues are in the United States and Europe. Basis of presentation and use of estimates The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). In preparing the Company’s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. In preparing the Company’s consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of IPR&D assets, marketed product rights and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could be impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. Government actions taken to address macroeconomic developments, as well as their economic impact on Teva’s third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. In February 2022, Russia launched an invasion of Ukraine. As of the date of these consolidated financial statements, sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva’s International Markets segment results. Teva has no manufacturing or R&D facilities in these markets. As part of the Company’s annual goodwill analysis performed in the second quarter of 2022, it identified an increase in the discount rate, which led to a goodwill impairment charge in its International Markets reporting unit. This increase was a result of an increase in certain components of the discount rate that were partially attributed to higher risk associated with country-specific characteristics of several countries, such as Russia, that might be a consequence of the conflict. Other than its impact on the goodwill impairment charge described above, during the year ended December 31, 2022, the impact of the Russia-Ukraine conflict on Teva’s results of operations and financial condition was immaterial. See also note 7. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. Functional currency A major part of the Group’s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (“dollar” or “$”). The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results net of related income taxes are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). Principles of consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and variable interest entities (“VIEs”) for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders’ interests are shown as non-controlling For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated.
New accounting pronouncements	b. New accounting pronouncements Recently adopted accounting pronouncements In November 2021, the FASB issued ASU 2021-10 in-scope In August 2020, the FASB issued ASU 2020-06 470-20) In March 2020, the FASB issued ASU 2020-04 adoption of this guidance did not have a material impact on the Company’s consolidated financial results of operations, financial position or cash flows. Recently issued accounting pronouncements, not yet adopted In September 2022, the FASB issued ASU 2022-04 405-50)”. In October 2021, the FASB issued ASU 2021-08
Acquisitions	c. Acquisitions: Teva’s consolidated financial statements include the operations of acquired businesses from the date of the acquisition’s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed unless it has an alternative future use. Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is re-measured
Collaborative arrangements	d. Collaborative arrangements: Collaborative arrangements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor.
Equity investments	e. Equity investments: The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative prescribed within ASU 2016-01
Fair value measurement	f. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
Cash and cash equivalents	g. Cash and cash equivalents: All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents.
Restricted cash	h. Restricted cash: Restricted cash represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet under other current assets.
Accounts receivables	i. Accounts Receivables: Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. Write-off
Concentration of credit risks	j. Concentration of credit risks: Most of Teva’s cash and cash equivalents (which, along with investment in securities, totaled $2,817 million at December 31, 2022) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 47% of Teva’s consolidated revenues in 2022. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance.
Inventories	k. Inventories: Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. Inventories acquired in a business combination are stepped-up
Long-lived assets	l. Long-lived assets: Teva’s long-lived, non-current right-of-use Goodwill Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any non-controlling assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. The goodwill impairment test is performed according to the following principles: 1. An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. 2. If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value is recognized. An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company’s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company’s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. Identifiable intangible assets Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (“FDA”) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (“S&M”) expenses when separable. Indefinite life intangible assets are mainly comprised of IPR&D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. IPR&D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset’s estimated life, calculates the undiscounted value of the asset’s or asset group’s cash flows and compares such value against the asset’s or asset group’s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. For indefinite life intangible assets, Teva performs an impairment test annually in the second quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Teva determines the fair value of the asset based on discounted cash flows and records an impairment loss if its book value exceeds fair value. In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company’s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i) for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii) for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. Property, plant and equipment Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly 20 years; and other assets, between 5 to 10 years. For property, plant and equipment and lease right-of-use Lease right-of-use See note 8 and note 1cc for further discussion.
Contingencies	m. Contingencies: The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are reasonably estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. When applicable, the Company classifies the effect that the passage of time had on the net present value of a discounted legal accrual as legal expenses. Legal costs are expensed as incurred. The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved.
Treasury shares	n. Treasury shares: Treasury shares are presented as a reduction of Teva shareholders’ equity and carried at their cost to Teva, under treasury shares. 103
Stock-based compensation	o. Stock-based compensation: Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (“RSUs”) and performance share units (“PSUs”). The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option’s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards and RSUs to expense over the vesting period on a straight-line basis. Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting. Teva records forfeitures for share-based awards, RSUs and PSUs as they occur. If an employee forfeits an award because he fails to complete the requisite service period, the Company will reverse the compensation cost previously recognized in the period the award is forfeited.
Deferred income taxes	p. Deferred income taxes: Deferred income taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as non-current. Tax has not been provided on the following items: 1. Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company’s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. 2. Amounts of tax-exempt
Uncertain tax positions	q. Uncertain tax positions: Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly re-evaluates Provisions for uncertain tax positions, whereas Teva has net o ting losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss.
Derivatives and hedging	r. Derivatives and hedging: The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company’s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. Derivative instruments are recognized on the balance sheet at their fair value. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses, net in the statements of income in the period that the changes in fair value occur. For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. For derivative instruments that are designated as net-investment For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. Derivative instruments that do not qualify for hedge accounting are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses, net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
Revenue recognition	s. Revenue recognition: A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“performance obligations”), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (“SR&A”) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&A components and how they are estimated, see “Variable Consideration” below. Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&M expenses. Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one year or less, based on the practical expedient. The Company’s credit terms to customers are, on average, between thirty and . The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. Nature of revenue streams Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. Licensing arrangements performance obligations generally include intellectual property (“IP”) rights, certain R&D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct – i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company’s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company’s IP. Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Revenues from licensing arrangements included royalty income of $212 million, $160 million and $129 million for the years ended December 31, 2022, 2021 and 2020, respectively. Distribution revenues are derived from sales of third-party products for which the Company acts as distributor, mostly in the United States via Anda and in Israel via Salomon Levin and Elstein Ltd. (SLE). In the United States, the Company is the principal in these arrangements and therefore records revenue on a gross basis as it controls the promised goods before transferring these goods to the customer. In Israel, the Company is the agent in these arrangements and therefore records revenue on a net basis as it has no discretion in establishing prices for any specified goods or services, limited inventory risk and is not primarily responsible for contract fulfillment. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. Other revenues are primarily comprised of contract manufacturing services, sales of medical devices and other miscellaneous items. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped, once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. Trade receivables and contract liabilities Trade receivables are presented net of allowance for credit losses, which include amounts billed and currently due from customers. Contract liabilities are mainly comprised of deferred revenues (defined as obligations to provide products or services to customers when payment has been made in advance and delivery or performance has not yet occurred), which were immaterial as of December 31, 2022 and 2021. Variable consideration Variable consideration mainly includes SR&A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated: Rebates Rebates are primarily related to volume incentives and are offered to key customers to promote loyalty. These rebate programs provide that, upon the attainment of pre-established Medicaid and Other Governmental Rebates Pharmaceutical manufacturers whose products are covered by the Medicaid program are required to provide a rebate to each state as a percentage of their average manufacturer’s price for generic products dispensed and “best price” for innovative products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. Chargebacks The Company has arrangements with various third parties, such as managed care organizations and drug store chains, establishing prices for certain of Teva’s products. While these arrangements are made between the Company and the customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with Teva’s concurrence, which establish the pricing for certain products which the wholesalers provide. Under either arrangement, Teva will issue a credit (referred to as a “chargeback”) to the wholesaler for the difference between the invoice price to the wholesaler and the customer’s contract prices. Provisions for chargebacks involve estimates of contract prices of over 2,000 products and multiple contracts with multiple wholesalers. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers and, therefore, will not necessarily fluctuate in proportion to an increase or decrease in sales. Provisions for estimating chargebacks are calculated using historical chargeback experience and/or expected chargeback levels for new products and anticipated pricing changes. Teva considers current and expected price competition when evaluating the provision for chargebacks. Chargeback provisions are compared to externally obtained distribution channel reports for reasonableness. The Company regularly monitors the provision for chargebacks and makes adjustments when the Company believes that actual chargebacks may differ from estimated provisions. Other Promotional Arrangements Other promotional or incentive arrangements are periodically offered to customers, specifically related to the launch of products or other targeted promotions. Provisions are made in the period for which the Company can estimate the incentive earned by the customer, in accordance with the contractual terms. The Company regularly monitors the provision for other promotional arrangements and makes adjustments when it believes that the actual provision may differ from the estimated provisions. Shelf Stock Adjustments The custom in the pharmaceutical industry is generally to grant customers a shelf stock adjustment based on the customers’ existing inventory contemporaneously with decreases in the market price of the related product. The most significant of these relate to products for which an exclusive or semi-exclusive period exists. Provisions for price reductions depend on future events, including price competition, new competitive launches and the level of customer inventories at the time of the price decline. Teva regularly monitors the competitive factors that influence the pricing of its products and customer inventory levels and adjust these estimates where appropriate. Returns Returns primarily relate to customer returns of expired products which, the customer has the right to return up to one year following the expiration date. Such returned products are destroyed and credits and/or refunds are issued to the customer for the value of the returns. Accordingly, no returned assets are recoded in connection with those products. The returns provision is estimated by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Revenue subject to returns is estimated based on the lag time from time of sale to date of return. The estimated lag time is developed by analyzing historical experience. Additionally, The Company considers specific factors, such as estimated levels of inventory in the distribution channel, product dating and expiration, size and maturity of launch, entrance of new competitors, changes in formularies or packaging and any changes to customer terms, for determining the overall expected levels of returns. Prompt Pay Discounts Prompt pay discounts are offered to most customers to encourage timely payment. Discounts are estimated at the time of invoice based on historical discounts in relation to sales. Prompt pay discounts are almost always utilized by customers. As a result, the actual discounts do not vary significantly from the estimated amount.
Research and development	t. Research and development: Research and development expenses are charged to statement of income (loss) as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the related goods are used or the services are rendered. Research and development in-process
Shipping and handling costs	u. Shipping and handling costs: Shipping and handling costs to end customers, which are included in S&M expenses, were $118 million, $111 million and $124 million for the years ended December 31, 2022, 2021 and 2020, respectively.
Advertising costs	v. Advertising costs: Advertising costs are expensed as incurred. Advertising costs for the years ended December 31, 2022, 2021 and 2020 were $168 million, $246 million and $225 million, respectively.
Restructuring	w. Restructuring: Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. Costs for one-time Contractual termination benefits are provided to employees when employment is terminated due to an event specified in the provisions of an existing plan or agreement. A liability is recorded and the expense is recognized when it is probable that employees will be entitled to the benefits and the amount is reasonably estimable. Special termination benefits arise when the Company offers, for a short period of time, to provide certain additional benefits to employees electing voluntary termination. A liability is recorded and the expense is recognized in the period the employees irrevocably accept the offer and the amount of the termination liability is reasonably estimable.
Segment reporting	x. Segment reporting: The Company’s business includes three reporting segments based on three geographical areas: (a) North America segment, which includes the United States and Canada. (b) Europe segment, which includes the European Union, the United Kingdom and certain other European countries. (c) International Markets segment, which includes all countries in which Teva operates other than those in the North America and Europe segments. Each business segment manages the entire product portfolio in its region, including generic products, innovative medicines and over-the-counter In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing
Earnings per share	y. Earnings per share: Basic earnings (loss) per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested RSUs and PSUs during the period, net of treasury shares. In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i) the exercise of options and non-vested “if-converted”
Securitization	z. Securitization Teva accounts for transfers of its trade receivable as sales when it has surrendered control over the related assets in accordance with ASC Topic 860 “Transfer and Servicing” of Financial Assets. Whether control has been relinquished requires, among other things, an evaluation of relevant legal considerations and an assessment of the nature and extent of the Company’s continuing involvement with the assets transferred. Assets obtained and liabilities incurred in connection with transfers reported as sales are initially recognized in the balance sheet at fair value. Refer to note 10f.
Divestitures	aa. Divestitures The Company nets the proceeds on the divestitures of products with the carrying amount of the related assets and records gain or loss on sale within other income. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when it is probable that a significant reversal of income will not occur, or in the case of a business, when such payments are realizable. For divestures of businesses, including divestitures of products that qualify as a business, the Company reflects the relative fair value of goodwill associated with the businesses in the determination of gain or loss on sale.
Debt instruments	bb. Debt instruments Debt instruments are initially recognized at the fair value of the consideration received. Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liability. They are subsequently recognized at amortized cost using the effective interest method. Debt may be considered extinguished when it has been modified and the terms of the new debt instruments and old debt instruments are “substantially different” (as defined in the debt modification guidance in ASC 470-50 non-current 470-50
Leases	cc. Leases Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. Operating leases are included in operating lease ROU assets, other current liabilities and operating lease liabilities in the consolidated balance sheet. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated balance sheet. ROU assets represent Teva’s right to use an underlying asset for the lease term and lease liabilities represent Teva’s obligation to make lease payments arising from the lease. Operating lease ROU and finance lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, which may include options to extend or terminate the lease, when it is reasonably certain at the commencement date whether the Company will or will not exercise the option to renew or terminate the lease. Teva uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. For finance leases, Teva recognizes interest on the lease liability separately from amortization of the assets in the consolidated statement of income. For operating leases, lease expenses are recognized on a straight-line basis over the lease term. Teva e non-lease Lease terms will include options to extend or terminate the lease when it is reasonably certain that Teva will either exercise or not exercise the option to renew or terminate the lease. Teva’s lease agreements have remaining lease terms ranging from 1 year to 76 years. Some of these agreements include options to extend the leases for up to 10 years and some include options to terminate the leases immediately. Certain leases also include options to purchase the leased property. The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise. Some of Teva’s vehicle lease agreements include rental payments based on the actual usage of the vehicles and other lease agreements include rental payments adjusted periodically for inflation. Teva’s lease agreements do not contain any material residual value guarantees. Teva rents out or subleases certain assets to third parties, which has an immaterial impact on Teva’s consolidated financial statements.

Certain transactions (Tables)

Certain transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Major Classes of Assets and Liabilities Included as Held for Sale	The table below summarizes all of Teva’s assets and liabilities included as held for sale as of December 31, 2022 and December 31, 2021: December 31, December 31, (U.S. $ in millions) Inventories 2 2 Property, plant and equipment, net and others 18 86 Goodwill — 7 Adjustments of assets held for sale to fair value (10 ) (76 ) Total assets of the disposal group classified as held for sale in $ 10 $ 19 Total liabilities of the disposal group classified as held for sale $ — $ (43 )

Revenue from contracts with c_2

Revenue from contracts with customers (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of disaggregates revenues by major revenue streams	The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. Year ended December 31, 2022 North Europe International Other Total (U.S.$ in millions) Sale of goods 5,834 4,455 1,806 671 12,766 Licensing arrangements 139 51 19 4 212 Distribution 1,471 1 46 — 1,519 Other 8 18 33 370 428 $ 7,452 $ 4,525 $ 1,903 $ 1,045 $ 14,925 Year ended December 31, 2021 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,394 4,807 1,889 739 13,829 Licensing arrangements 92 50 13 4 160 Distribution 1,323 1 65 — 1,390 Other (1 ) 27 65 408 500 $ 7,809 $ 4,886 $ 2,032 $ 1,151 $ 15,878 Year ended December 31, 2020 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,902 4,736 1,946 772 14,354 Licensing arrangements 84 32 9 4 129 Distribution 1,462 3 30 — 1,495 Other § (14 ) 169 527 680 $ 8,447 $ 4,757 $ 2,154 $ 1,302 $ 16,659 § Represents an amount less than $1 million.
Summary of Sales Reserves and Allowances	The changes in SR&A for third-party sales for the period ended December 31, 2022 and 2021 were as follows: Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Sales Reserves and Total (U.S.$ in millions) Balance at January 1, 2022 $ 68 $ 1,655 $ 854 $ 1,085 $ 535 $ 112 $ 4,241 $ 4,309 Provisions related to sales made in current 363 3,823 871 7,819 317 85 12,915 13,278 Provisions related to sales made in prior — (69 ) (35 ) (44 ) (3 ) (51 ) (202 (202 ) Credits and payments (364 ) (3,798 ) (1,023 ) (7,861 ) (390 ) (77 ) (13,149 (13,513 ) Translation differences — (36 ) (4 ) (8 ) (4 ) (3 ) (55 (55 ) Balance at December 31, 2022 $ 67 $ 1,575 $ 663 $ 991 $ 455 $ 66 $ 3,750 $ 3,817 Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Total (U.S.$ in millions) Balance at January 1, 2021 $ 80 $ 2,054 $ 828 $ 1,108 $ 686 $ 148 $ 4,824 $ 4,904 Provisions related to sales made in current year period 382 4,030 852 7,967 263 314 13,426 13,808 Provisions related to sales made in prior periods (9 ) (125 ) (51 ) (47 ) (60 ) (26 ) (309 ) (318 ) Credits and payments (385 ) (4,275 ) (768 ) (7,937 ) (350 ) (321 ) (13,651 ) (14,036 ) Translation differences — (29 ) (7 ) (6 ) (4 ) (3 ) (49 ) (49 ) Balance at December 31, 2021 $ 68 $ 1,655 $ 854 $ 1,085 $ 535 $ 112 $ 4,241 $ 4,309

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Inventories	Inventories, net of reserves, consisted of the following: December 31, 2022 2021 (U.S. $ in millions) Finished products $ 1,987 $ 1,932 Raw and packaging materials 1,059 1,136 Products in process 555 587 Materials in transit and payments on account 232 163 $ 3,833 $ 3,818 11 6

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Property, Plant and Equipment, Net	Property, plant and equipment, net, consisted of the following: December 31, 2022 2021 (U.S. $ in millions) Machinery and equipment $ 5,026 $ 5,098 Buildings 2,463 2,568 Computer equipment and other assets 2,323 2,261 Assets under construction and payments on account 1,199 1,034 Land 246 262 11,257 11,223 Less—accumulated depreciation (5,518 ) (5,241 ) $ 5,739 $ 5,982

Identifiable Intangible Assets

Identifiable Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Identifiable Intangible Assets	Identifiable intangible assets consisted of the following: Gross carrying amount Accumulated Net carrying amount December 31, 2022 2021 2022 2021 2022 2021 (U.S. $ in millions) Product rights $ 18,067 $ 18,815 $ 12,630 $ 12,318 $ 5,437 $ 6,497 Trade names 577 590 231 198 346 392 In-process 487 577 — — 487 577 Total $ 19,131 $ 19,982 $ 12,861 $ 12,516 $ 6,270 $ 7,466

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Changes in the Carrying Amount of Goodwill by Segment	The changes in the carrying amount of goodwill for the years ended December 31, 2022 and 2021 were as follows: North Europe International Other Total (U.S. $ in millions) Balance as of December 31, 2020 (1) $ 6,473 $ 9,102 $ 2,362 $ 2,687 $ 20,624 Changes during the period: Goodwill reclassified as assets held for sale — (7 ) — (11 ) (18 ) Translation differences 1 (551 ) (34 ) 18 (566 ) Balance as of December 31, 2021 (1) $ 6,474 $ 8,544 $ 2,328 $ 2,694 $ 20,040 Changes during the period: Goodwill impairment — — (979 ) (1,066 ) (2,045 ) Goodwill acquired — — — 12 12 Translation differences (24 ) (242 ) (10 ) (98 ) (374 ) Balance as of December 31, 2022 (1) (*) $ 6,450 $ 8,302 $ 1,339 $ 1,542 $ 17,633 (1) Accumulated goodwill impairment as of December 31, 2022, December 31, 2021 and December 31, 2020 was approximately $27.6 billion, $25.6 billion and $25.6 billion, respectively. (*) As of December 31, 2022, “Other” includes $1,293 million goodwill balance related to Teva’s API reporting unit.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Components Of Lease Expense	The components of operating lease cost for the years ended December 31, 2022, 2021 and 2020 were as follows: Year ended Year ended Year ended 2022 2021 2020 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Operating lease cost: Fixed payments and variable payments that depend on an index or rate $ 142 $ 135 $ 148 Variable lease payments not included in the lease liability 4 4 4 Short-term lease cost 2 2 3 $ 148 $ 141 $ 155
Supplemental cash flow information related to leases	Supplemental cash flow information related to operating leases was as follows: Year ended Year ended Year ended 2022 2021 2020 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 140 $ 143 $ 151 Right-of-use (non-cash): Operating leases $ 81 $ 81 $ 211
Supplemental Balance Sheet Information Related To Leases	Supplemental balance sheet information related to operating leases was as follows: December 31, December 31, 2022 2021 (U.S. $ in millions) (U.S. $ in millions) Operating leases: Operating lease ROU assets $ 419 $ 495 Other current liabilities 93 109 Operating l eas iabilit 349 416 Total operating lease liabilities $ 442 $ 525 December 31, December 31, 2022 2021 Weighted average remaining lease term Operating leases 6.8 years 7.3 years Weighted average discount rate Operating leases 5.6 % 5.4 %
Maturities of lease liabilities	Maturities of operating lease liabilities were as follows: December 31, 2022 (U.S. $ in millions) 202 3 116 202 4 94 202 5 79 202 6 66 202 7 188 Total operating lease payments $ 543 Less: imputed interest 101 Present value of lease liabilities $ 442

Debt obligations (Tables)

Debt obligations (Tables)	12 Months Ended
	Dec. 31, 2022
Schedule of Short-term Debt	a. Short-term debt: December 31, Weighted average interest rate as of Maturity 2022 2021 (U.S. $ in millions) Convertible debentures 0.25 % 2026 23 23 Current maturities of long-term liabilities 2,086 1,403 Total short term debt $ 2,109 $ 1,426
Schedule of Senior Notes and Loans	b. Long-term debt: Weighted average Maturity December 31, December 31, % (U.S. $ in millions) Senior notes EUR 1,500 million 1.13 % 2024 670 708 Sustainability-linked senior notes EUR 1,500 million (1)(*) 4.38 % 2030 1,606 1,699 Senior notes EUR 1.25 % 2023 633 670 Sustainability-linked senior notes EUR 1,100 million (2)(*) 3.75 % 2027 1,177 1,246 Senior notes EUR 1,000 million 6.00 % 2025 1,070 1,134 Senior notes EUR 900 million 4.50 % 2025 963 1,020 Senior notes EUR 1.63 % 2028 800 844 Senior notes EUR 700 million (3) 3.25 % 2022 — 307 Senior notes EUR 700 million 1.88 % 2027 748 792 Senior notes USD 3,500 million 3.15 % 2026 3,496 3,496 Senior notes USD 3,000 million 2.80 % 2023 1,453 1,453 Senior notes USD 2,000 million 4.10 % 2046 1,986 1,986 Senior notes USD 1,250 million 6.00 % 2024 1,250 1,250 Senior notes USD 1,250 million 6.75 % 2028 1,250 1,250 Senior notes USD 1,000 million 7.13 % 2025 1,000 1,000 Sustainability-linked senior notes USD 1,000 million (2)(*) 4.75 % 2027 1,000 1,000 Sustainability-linked senior notes USD 1,000 million (1)(*) 5.13 % 2029 1,000 1,000 Senior notes USD 844 million (5) 2.95 % 2022 — 715 Senior notes USD 789 million 6.15 % 2036 783 783 Senior notes CHF 350 million (4) 0.50 % 2022 — 382 Weighted average Maturity December 31, December 31, % (U.S. $ in millions) Senior notes CHF 350 million 1.00 % 2025 382 383 Total senior notes 21,266 23,118 Other long-term debt 1 2 Less current maturities (2,086 ) (1,403 ) Less debt issuance costs (78 ) (100 ) Total senior notes and loans $ 19,103 $ 21,617 (1) If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% (2) If Teva fails to achieve certain sustainability performance targets, a one-time 0.15%-0.45% (3) In April 2022, Teva repaid $296 million of its 3.25% senior notes at maturity. (4) In July 2022, Teva repaid $365 million of its 0.50% senior notes at maturity. (5) In December 2022, Teva repaid $713 million of its 2.95% senior notes at maturity. (*) Interest rate adjustments and a potential one-time
Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost	As of December 31, 2022, the required annual principal payments of long-term debt (excluding debt discount and issuance costs and fair value hedge adjustments), including convertible senior debentures, starting from the year 2024, are as follows: December 31, (U.S. $ in millions) 2024 $ 1,921 2025 3,412 2026 * 3,523 2027 2,927 2028 and thereafter 7,448 $ 19,231 * I

Derivative instruments and he_2

Derivative instruments and hedging activities (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Classification and Fair Values of Derivative Instruments	The following table summarizes the classification and fair values of derivative instruments: Fair value Not designated as hedging instruments December 31, 2022 December 31, 2021 Reported under (U.S. $ in millions) Asset derivatives: Other current assets: Option and forward contracts $ 29 $ 30 Liability derivatives: Other current liabilities: Option and forward contracts $ (101 ) $ (23 )
Derivatives Not Designated as Hedging Instruments	The table below provides information regarding the location and amount of pre-tax Reported under Financial expenses, net Other comprehensive income (loss) Year ended December 31, Year ended December 31, 2022 2021 2020 2022 2021 2020 (U.S. $ in millions) Line items in which effects of hedges are recorded $ 966 $ 1,058 $ 834 $ (270 ) $ (391 ) $ (30 ) Cross-currency swaps—net investment hedge (1) — — (2 ) — — (21 )
Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships
Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program	The following table summarizes the change in the sold receivables outstanding balance, net of DPP, under the outstanding securitization program: As of and for the year ended 2022 2021 (U.S. $ in millions) Sold receivables at the beginning of the year $ 685 $ 734 Proceeds from sale of receivables 4,653 5,139 Cash collections (remitted to the owner of the receivables) (4,665 ) (5,152 ) Effect of currency exchange rate changes (37 ) (36 ) Sold receivables at the end of the year $ 636 $ 685

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Schedule of Income Before Income Taxes	a. Income (loss) before income taxes: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Parent Company and its Israeli subsidiaries $ (119 ) $ 126 $ 947 Non-Israeli (2,946 ) 532 (5,353 ) $ (3,065 ) $ 658 $ (4,406 )
Schedule of the Provision for Income Taxes	b. Income taxes: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) In Israel $ 33 $ 124 $ 60 Outside Israel (671 ) 87 (228 ) $ (638 ) $ 211 $ (168 ) Current $ 430 $ 270 $ 182 Deferred (1,068 ) (59 ) (350 ) $ ) $ 211 $ (168 )
Accumulated Other Comprehensive Income/(Loss) (Net of Tax)	Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Income (loss) before income taxes $ (3,065) $ 658 $ (4,406) Statutory tax rate in Israel 23% 23% 23% Theoretical provision for income taxes $ (705) $ 151 $ (1,013) Increase (decrease) in the provision for income taxes due to: The Parent Company and its Israeli subsidiaries - Tax benefits arising from reduced tax rates under benefit programs 15 (12) (153) Mainly nondeductible items and prior year tax 35 20 (30) Non-Israeli 924 117 1,369 Worthless stock deduction (**) (909) — — Increase (decrease) in other uncertain tax positions—net 2 (65) (341) Effective consolidated income taxes $ (638) $ 211 $ (168) * In 2022 and 2020, loss non-Israeli ** In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva will recognize on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million.
Schedule of Deferred Income Taxes	c. Deferred income taxes: December 31, 2022 2021 (U.S. $ in millions) Deferred tax assets (liabilities), net: Inventory related $ 125 $ 104 Sales reserves and allowances 89 136 Provision for legal settlements 703 360 Intangible assets (*) (567 ) (814 ) Carryforward losses and deductions and credits (**) 2,850 2,093 Property, plant and equipment (238 ) (215 ) Deferred interest 800 617 Provisions for employee related obligations 82 95 Other 133 159 3,977 2,535 Valuation allowance—in respect of carryforward losses and deductions that may not be (3,072 ) (2,723 ) $ 905 $ (188 ) (*) The decrease in deferred tax liability is mainly due to impairment and amortization. (**) The amounts are shown following a reduction for unrecognized tax benefits of $1 million and $10 million as of December 31, 2022 and 2021, respectively.
Schedule of Deferred Tax Assets and Liabilities By Report Caption	The deferred income taxes are reflected in the balance sheet among: December 31, 2022 2021 (U.S. $ in millions) Long-term assets—deferred income taxes 1,453 596 Long-term liabilities—deferred income taxes (548 ) (784 ) $ 905 $ (188 )
Schedule of Unrecognized Tax Benefits	d. Uncertain tax positions: The following table summarizes the activity of Teva’s gross unrecognized tax benefits: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Balance at the beginning of the year $ 672 $ 888 $ 1,223 Increase (decrease) related to prior year tax positions, net (46 ) (106 ) (238 ) Increase related to current year tax positions 42 7 10 Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations (31 ) (115 ) (105 ) Other 1 (2 ) (2 ) Balance at the end of the year $ 638 $ 672 $ 888

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Stock Option Activity	A summary of the status of the options granted by Teva as of December 31, 2022, 2021 and 2020, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). Year ended December 31, 2022 2021 2020 Number (in thousands) Weighted Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 29,015 $ 36.96 35,234 $ 37.27 40,064 $ 37.90 Changes during the year: Forfeited (2,378 ) 33.77 (3,644 ) 36.09 (3,610 ) 40.24 Expired (2,518 ) 41.26 (2,575 ) 42.40 (1,220 ) 49.35 Balance outstanding at end of year 24,119 36.83 29,015 36.96 35,234 37.27 Balance exercisable at end of year 24,119 36.83 26,989 38.30 28,556 40.56 No options were granted during 2022, 2021 and 2020.
Schedule of Ordinary Shares Issued Upon Vested Options	The following table summarizes information as of December 31, 2022 regarding the number of ordinary shares issuable upon vested options: Number of ordinary shares issuable upon exercise of vested options Range of exercise prices Balance at end of period (in thousands) Weighted average Weighted average Number of shares $ Years Lower than $15.01 592 11.40 4.84 $15.01 - $25.00 7,781 18.96 5.13 $25.01 - $35.00 5,712 34.61 4.16 $35.01 - $45.00 509 38.13 0.57 $45.01 - $55.00 5,906 51.30 2.36 $55.01 - $65.00 3,619 59.10 2.33 Total 24,119 36.83 3.70
Schedule of the Number of RSUs Issued and Outstanding	The following table summarizes information about the number of RSUs and PSUs granted and outstanding: Year ended December 31, 2022 2021 2020 Number (in thousands) Weighted grant date fair value Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 24,412 $ 11.58 20,720 $ 13.81 15,977 $ 16.49 Granted 18,755 7.42 12,748 10.42 10,848 11.42 Vested (7,571 ) 13.02 (6,818 ) 15.60 (4,324 ) 19.49 Forfeited (3,293 ) 9.81 (2,238 ) 12.18 (1,781 ) 18.18 Balance outstanding at end of year 32,302 9.11 24,412 11.58 20,720 13.81
Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value	The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2022, 2021 and 2020, the Company recorded stock-based compensation costs as follows: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Employee stock options $ 2 $ 16 $ 30 RSUs and PSUs 122 103 99 Total stock-based compensation expense 124 119 129 Tax effect on stock-based compensation expense 9 12 14 Net effect $ 115 $ 107 $ 115
Accumulated Other Comprehensive Income/(Loss) (Net of Tax)	The components of accumulated other comprehensive loss attributable to Teva are presented in the table below: Net Unrealized Gains/(Losses) Benefit Plans Foreign Derivative Actuarial Total (U.S. $ in millions) Balance as of January 1, 2020 $ (1,794 ) (420 ) (98 ) (2,312 ) Other comprehensive income/(loss) before reclassifications (190 ) 22 (7 ) (175 ) Amounts reclassified to the statements of income — 35 (12 ) 23 Net other comprehensive income/(loss) before tax (190 ) 57 (19 ) (152 ) Corresponding income tax 65 — 1 66 Net other comprehensive income/(loss) after tax* (125 ) 57 (18 ) (86 ) Balance as of December 31, 2020 (1,919 ) (363 ) (117 ) (2,399 ) Other comprehensive income/(loss) before reclassifications (386 ) — 18 (368 ) Amounts reclassified to the statements of income — 39 18 57 Net other comprehensive income/(loss) before tax (386 ) 39 36 (311 ) Corresponding income tax 31 — (4 ) 27 Net other comprehensive income/(loss) after tax* (355 ) 39 32 (284 ) Balance as of December 31, 2021 (2,274 ) (324 ) (85 ) (2,683 ) Other comprehensive income/(loss) before reclassifications (223 ) — 40 (183 ) Amounts reclassified to the statements of income — 29 27 56 Net other comprehensive income/(loss) before tax (223 ) 29 67 (127 ) Corresponding income tax (17 ) — (10 ) (27 ) Net other comprehensive income/(loss) after tax* (240 ) 29 57 (154 ) Balance as of December 31, 2022 $ (2,514 ) $ (295 ) $ (28 ) $ (2,838 ) * Amounts do not include foreign currency translation adjustments attributable to non-controlling

Other assets impairments, res_2

Other assets impairments, restructuring and other items (Tables)	12 Months Ended
	Dec. 31, 2022
Schedule of Other Assets Impairments, Restructuring and Other Items	Year ended December 31, 2022 2021 2020 (U.S. $ in millions) I mpairmen $ 47 $ 160 $ 416 Contingent consideration (see note 20) 163 7 (81 ) Restructuring 146 133 120 Other 57 41 24 Total $ 414 $ 341 $ 479 (1) Including impairments related to exit and disposal activities.
Summary of Restructuring Plan Including Costs Related to Exit and Disposal	The following tables provide the components of restructurin g costs: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Restructuring Employee termination $ 117 $ 117 $ 71 Other 29 16 49 Total $ 146 $ 133 $ 120 157
Summary of Restructuring Accruals	The following table provides the components of and changes in the Company’s restructuring accruals: Employee Other Total (U.S. $ in millions ) Balance as of January 1, 2020 $ (208 ) $ (7 ) $ (215 ) Provision (71 ) (49 ) (120 ) Utilization and other* 164 49 213 Balance as of January 1, 2021 $ (115 ) $ (7 ) $ (122 ) Provision (117 ) (16 ) (133 ) Utilization and other* 101 16 117 Balance as of December 31, 2021 $ (131 ) $ (7 ) $ (138 ) Provision (117 ) (29 ) (146 ) Utilization and other* 136 29 165 Balance as of December 31, 2022 $ (112 ) (7 ) (119 ) * Includes adjustments for foreign currency translation.

Other income (Tables)

Other income (Tables)	12 Months Ended
	Dec. 31, 2022
Schedule of Other Income	Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Gain on divestitures, net of divestitures related costs (1) $ 46 51 8 Section 8 and similar payments (2) 13 19 — Gain (loss) on sale of assets 18 7 11 Other, net (3) 31 22 20 Total other income $ 107 $ 98 $ 40 (1) In 2022, mainly related to the divestment of several activities in North America and International Markets. In 2021, mainly due to capital gains related to the sale of certain OTC assets. In 2020, mainly related to the divestment of several activities in International Markets. (2) Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada. (3) In 2022, mainly the result of settlement proceeds related to the International Markets segment.

Financial expenses, net (Tables

Financial expenses, net (Tables)	12 Months Ended
	Dec. 31, 2022
Schedule of Financial Expenses	Year ended December, 31 2022 2021 2020 (U.S. $ in millions) Interest expenses and other bank charges 930 891 901 (Income) loss from investments (1) (10 ) 90 (104 ) Foreign exchange (gains) losses, net (16 ) 7 (26 ) Other, net (2) 61 71 62 Total finance expense, net $ 966 $ 1,058 $ 834 (1) (Income) loss from investments in 2021 and 2020 comprised mainly of revaluation gains and loss of Teva’s investment in American Well Corporation (“American Well”). (2) Amortization of issuance costs and terminated derivative instruments.

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Schedule of Earnings per Share	The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2022, 2021 and 2020 are as follows: Year ended December, 31 2022 2021 2020 (U.S. $ in millions, except share data) Net income (loss) used for the computation of basic and diluted earnings (loss) per share (2,353 ) $ 417 $ (3,990 ) Weighted average number of shares used in the computation of basic earnings (loss) per share 1,110 1,102 1,095 Weighted average number of shares used in the computation of diluted earnings (loss) per share 1,110 1,107 1,095

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Segment Profit	a. Segment information: Year ended December 31, 2022 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,452 $ 4,525 $ 1,903 Gross profit 3,926 2,700 1,033 R&D expenses 532 213 72 S&M expenses 941 748 405 G&A expenses 474 246 119 Other income (15 ) (3 ) (43 ) Segment profit $ 1,993 $ 1,496 $ 479 Year ended December 31, 2021 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,809 $ 4,886 $ 2,032 Gross profit 4,226 2,823 1,118 R&D expenses 618 244 68 S&M expenses 988 846 417 G&A expenses 427 244 109 Other income (31 ) (5 ) (5 ) Segment profit $ 2,224 $ 1,494 $ 529 Year ended December 31, 2020 North America Europe International Markets (U.S. $ in millions) Revenues $ 8,447 $ 4,757 $ 2,154 Gross profit 4,489 2,666 1,096 R&D expenses 622 247 70 S&M expenses 1,013 830 427 G&A expenses 443 261 136 Other income (10 ) (3 ) (11 ) Segment profit $ 2,421 $ 1,331 $ 474
Schedule Of Consolidated Income Before Income Tax	Year ended December 31, 2022 2021 2020 (U.S. $ in millions) North America profit $ 1,993 $ 2,224 $ 2,421 Europe profit 1,496 1,494 1,331 International Markets profit 479 529 474 Total reportable segments profit 3,968 4,246 4,225 Profit of other activities 172 154 163 Total segments profit 4,140 4,401 4,388 Amounts not allocated to segments: Amortization 732 802 1,020 Other assets impairments, restructuring and other items 414 341 479 Goodwill impairment 2,045 — 4,628 Intangible asset impairments 355 424 1,502 Legal settlements and loss contingencies 2,082 717 60 Other unallocated amounts 610 402 271 Consolidated operating income (loss) (2,099 ) 1,716 (3,572 ) Financial expenses, net 966 1,058 834 Consolidated income (loss) before income taxes $ (3,065 ) $ 658 $ (4,406 )
Schedule of Net Sales by Product Line	The following tables present revenues by major products and activities for each segment for the year ended December 31, 2022, 2021 and 2020: North America segment: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Generic products $ 3,549 $ 3,769 $ 4,010 AJOVY 218 176 134 AUSTEDO 963 802 637 BENDEKA and TREANDA 316 385 415 COPAXONE 387 577 884 Anda 1,471 1,323 1,462 Other 549 777 905 Total $ 7,452 $ 7,809 $ 8,447 Europe segment: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Generic products $ 3,466 $ 3,569 $ 3,513 AJOVY 124 87 31 COPAXONE 268 391 400 Respiratory products 273 356 353 Other 393 483 459 Total $ 4,525 $ 4,886 $ 4,757 International Markets segment: Year ended December 31, 2022 2021 2020 (U.S. $ in millions) Generic products $ 1,586 $ 1,649 $ 1,792 AJOVY 35 50 18 COPAXONE 36 37 53 Other 246 295 291 Total $ 1,903 $ 2,032 $ 2,154
Schedule of Sales Percentage by Therapeutic Category	The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2022, 2021 and 2020. Percentage of Third Party Net Sales 2022 2021 2020 McKesson Corporation 10 % 11 % 12 % AmerisourceBergen Corporation 10 % 11 % 12 %
Schedule of Property, Plant and Equipment by Geographic Location	December 31, 2022 2021 (U.S. $ in millions) Israel $ 1,401 $ 1,543 Germany 1,143 1,045 United States 625 692 Croatia 445 481 Czech republic 318 324 Hungary 294 321 Ireland 268 269 Other 1,245 1,307 Total property, plant and equipment $ 5,739 $ 5,982

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Financial Items Carried at Fair Value	Financial items carried at fair value as of December 31, 2022 and 2021 are classified in the tables below in one of the three categories described in note 1f: December 31, 2022 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 1,222 — — $ 1,222 Cash, deposits and other 1,579 — — 1,579 Investment in securities: Equity securities 9 — — 9 Other 5 — 1 6 Restricted cash 33 — — 33 Derivatives: Asset derivatives : O s — 29 — 29 Liabilities derivatives — Options and forward contracts — (101 ) — (101 ) Bifurcated embedded derivatives — — § — Contingent consideration* — — (153 ) (153 ) Total $ 2,848 $ (73 ) $ (152 ) $ 2,624 § Represents an amount less than 0.5 million * Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.. December 31, 2021 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 220 — — $ 220 Cash, deposits and other 1,945 — — 1,945 Investment in securities: Equity securities 18 — — 18 Other 6 — 1 7 Restricted cash 33 — — 33 Derivatives: Asset derivatives: Options and forward contracts — 30 — 30 Liability derivatives: Options and forward contracts — (23 ) — (23 ) Bifurcated embedded derivatives — — § — Contingent consideration* — — (176 ) (176 ) Total $ 2,222 $ 7 $ (175 ) $ 2,054 § Represents an amount less than $0.5 million. * Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.
Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs	The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs. December 31, December 31, (U.S. $ in millions) Fair value at the beginning of the period $ (175 ) $ (258 ) Redemption of debt securities — (9 ) Bifurcated embedded derivatives § § Adjustments to provisions for contingent consideration: Actavis Generics transaction (142 ) 15 Eagle transaction (21 ) (23 ) Settlement of contingent consideration: Actavis Generics transaction 109 100 Eagle transaction 88 — Additional contingent consideration resulting from Novetide acquisition* (11 ) — Fair value at the end of the period $ (152 ) $ (175 ) § Represents an amount less than 0.5 million. * In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated companies”. This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under “Share in (profits) losses of associated companies, net”, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition.
Summary of Financial Instrument Measured on a Basis Other Than Fair Value	Financial instruments measured on a basis other than fair value consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value: Estimated fair value* December 31, 2022 2021 (U.S. $ in millions) Senior notes and sustainability-linked senior notes included under senior notes and loans $ 16,694 $ 21,477 Senior notes and convertible senior debentures included under short-term debt 2,075 1,426 Total $ 18,769 $ 22,903 * The fair value was estimated based on quoted market prices.

Long-term Employee-related Ob_2

Long-term Employee-related Obligations (Tables)	12 Months Ended
	Dec. 31, 2022
Schedule of Long Term Employee Related Obligation	a. Long-term employee-related obligations consisted of the following: December 31, 2022 2021 (U.S. $ in millions) Accrued severance obligations $ 74 $ 83 Defined benefit plans 58 142 Total $ 132 $ 225

Significant Accounting Polici_3

Significant Accounting Policies - Additional information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Significant Accounting Policies [Line Items]
Cash deposited with financially sound European us and Israeli banks and financial institutions	$ 2,817
Percentage of consolidated sales in North America	47%
Shipping and handling costs, which are included in selling and marketing expenses	$ 118	$ 111	$ 124
Advertising expense	$ 168	246	225
Operating Lease description	Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva’s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.
Royalty income	$ 212	$ 160	$ 129
Building [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	40 years
Other Machinery and Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	20 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Credit terms to customers	30 days
Operating Lease Remaining Lease Term	1 year
Minimum [Member] | Other Capitalized Property Plant and Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	5 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Credit terms to customers	90 days
Operating Lease Remaining Lease Term	76 years
Maximum [Member] | Other Capitalized Property Plant and Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	10 years

Certain Transactions - Other Tr

Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($) $ in Millions

1 Months Ended

3 Months Ended

12 Months Ended

Jan. 08, 2018

May 12, 2017

Oct. 31, 2021

Aug. 31, 2021

Dec. 31, 2016

Sep. 30, 2016

Sep. 30, 2022

Jun. 30, 2022

Dec. 31, 2021

Sep. 30, 2021

Sep. 30, 2020

Sep. 30, 2016

Dec. 31, 2022

Dec. 31, 2020

Dec. 31, 2018

Dec. 31, 2017

Alder [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 25

Milestone payment

$ 25

Collaborative agreement milestone payments

$ 150

Otsuka [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 50

Milestone payment

$ 35

$ 15

Takeda [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 30

Milestone payment

20

$ 25

Collaborative agreement milestone payments

$ 519

Regeneron [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 250

Collaborative agreement milestone payments

$ 120

$ 120

Research and development costs

$ 1,000

Alvotech [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Collaborative agreement milestone payments

$ 398

MedinCell [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Milestone payment

$ 3

Collaborative agreement milestone payments

$ 112

MODAG [Member]

Noncash or Part Noncash Acquisitions [Line Items]

License agreement potential aggregate milestone payments amount

$ 40

MODAG [Member] | Research and Development Expense [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Milestone payment

$ 10

Certain Transactions - Business

Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Business Combinations [Abstract]
Inventories	$ 2	$ 2
Property, plant and equipment, net and others	18	86
Goodwill		7
Adjustments of assets held for sale to fair value	(10)	(76)
Total assets of the disposal group classified as held for sale in the consolidated balance sheet	10	19
Total liabilities of the disposal group classified as held for sale in the consolidated balance sheet, recorded under accrued expenses and other long-term liabilities	$ 0	$ (43)

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Nov. 22, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue Recognition [Line Items]
Allowance for credit losses	$ 91		$ 90
Accounts receivable from securitization	$ 636		$ 685	$ 734
Pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022 [Member]
Revenue Recognition [Line Items]
Accounts receivable from securitization		$ 436
United States [Member]
Revenue Recognition [Line Items]
Percentage sales reserves and allowances to U.S. customers	71%

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 14,925	$ 15,878	$ 16,659
Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	12,766	13,829	14,354
Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	212	160	129
Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,519	1,390	1,495
Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	428	500	680
International Markets [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,903	2,032	2,154
International Markets [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,806	1,889	1,946
International Markets [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	19	13	9
International Markets [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	46	65	30
International Markets [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	33	65	169
Other activities [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,045	1,151	1,302
Other activities [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	671	739	772
Other activities [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	4	4	4
Other activities [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	0	0	0
Other activities [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	370	408	527
North America [Member]
Disaggregation of Revenue [Line Items]
Total revenue	7,452	7,809	8,447
North America [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	5,834	6,394	6,902
North America [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	139	92	84
North America [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,471	1,323	1,462
North America [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	8	(1)
Europe [Member]
Disaggregation of Revenue [Line Items]
Total revenue	4,525	4,886	4,757
Europe [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	4,455	4,807	4,736
Europe [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	51	50	32
Europe [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1	1	3
Europe [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 18	$ 27	$ (14)

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue Recognition [Line Items]
Balance at beginning of period	$ 4,309	$ 4,904
Provisions related to sales made in current year period	13,278	13,808
Provisions related to sales made in prior periods	(202)	(318)
Credits and payments	(13,513)	(14,036)
Translation differences	(55)	(49)
Balance at end of period	3,817	4,309
Reserves Included in Accounts Receivable, Net [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	68	80
Provisions related to sales made in current year period	363	382
Provisions related to sales made in prior periods	0	(9)
Credits and payments	(364)	(385)
Translation differences	0	0
Balance at end of period	67	68
Rebates [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	1,655	2,054
Provisions related to sales made in current year period	3,823	4,030
Provisions related to sales made in prior periods	(69)	(125)
Credits and payments	(3,798)	(4,275)
Translation differences	(36)	(29)
Balance at end of period	1,575	1,655
Medicaid and Other Governmental Allowances [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	854	828
Provisions related to sales made in current year period	871	852
Provisions related to sales made in prior periods	(35)	(51)
Credits and payments	(1,023)	(768)
Translation differences	(4)	(7)
Balance at end of period	663	854
Chargebacks [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	1,085	1,108
Provisions related to sales made in current year period	7,819	7,967
Provisions related to sales made in prior periods	(44)	(47)
Credits and payments	(7,861)	(7,937)
Translation differences	(8)	(6)
Balance at end of period	991	1,085
Returns [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	535	686
Provisions related to sales made in current year period	317	263
Provisions related to sales made in prior periods	(3)	(60)
Credits and payments	(390)	(350)
Translation differences	(4)	(4)
Balance at end of period	455	535
Other [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	112	148
Provisions related to sales made in current year period	85	314
Provisions related to sales made in prior periods	(51)	(26)
Credits and payments	(77)	(321)
Translation differences	(3)	(3)
Balance at end of period	66	112
Total Reserves Included in Sales Reserves and Allowances [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	4,241	4,824
Provisions related to sales made in current year period	12,915	13,426
Provisions related to sales made in prior periods	(202)	(309)
Credits and payments	(13,149)	(13,651)
Translation differences	(55)	(49)
Balance at end of period	$ 3,750	$ 4,241

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Inventories [Line Items]
Finished products	$ 1,987	$ 1,932
Raw and packaging materials	1,059	1,136
Products in process	555	587
Materials in transit and payments on account	232	163
Total	$ 3,833	$ 3,818

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Machinery and equipment	$ 5,026	$ 5,098
Buildings	2,463	2,568
Computer equipment and other assets	2,323	2,261
Assets under construction and payments on account	1,199	1,034
Land	246	262
Subtotal	11,257	11,223
Less—accumulated depreciation	(5,518)	(5,241)
Property, Plant and Equipment, Net, Total	$ 5,739	$ 5,982

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Depreciation expense for the year	$ 576	$ 528	$ 537
Impairment charge during the year on property, plant and equipment	47	160	416
Teva [Member]
Property, Plant and Equipment [Line Items]
Impairment charge during the year on property, plant and equipment	$ 47	$ 160	$ 416

Identifiable Intangible Asset_2

Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	$ 19,131	$ 19,982
Accumulated amortization	12,861	12,516
Net carrying amount	6,270	7,466
Product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	18,067	18,815
Accumulated amortization	12,630	12,318
Net carrying amount	5,437	6,497
Trade names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	577	590
Accumulated amortization	231	198
Net carrying amount	346	392
In-process research and development (IPR&D) [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	487	577
Net carrying amount	$ 487	$ 577

Identifiable Intangible Asset_3

Identifiable Intangible Assets - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets useful life	9 years
Amortization of intangible assets	$ 732	$ 802	$ 1,020
2023	597
2024	531
2025	490
2026	493
2027	485
Impairment of intangible assets excluding goodwill	355	424	1,502
Inventory write down	4,200
Change In Tevas Commercial Plans Regarding Certain Program [Member]
Finite-Lived Intangible Assets [Line Items]
Inventory write down	$ 108
Minimum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	8.5
Maximum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	11
Lenalidomide Product [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			262
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			797
In Process Research and Development [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	7.25
In Process Research and Development [Member] | Minimum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	20
In Process Research and Development [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	11
In Process Research and Development [Member] | Maximum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	90
In Process Research and Development [Member] | Generic Pipeline Products [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	$ 45	127
Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	310		705
Identifiable product rights [Member] | Updated Market Assumptions [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	256
Identifiable product rights [Member] | Change In Tevas Commercial Plans Regarding Certain Program [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	$ 54
Identifiable product rights [Member] | Lenalidomide Product [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		267
Actavis [Member] | In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			110
Actavis [Member] | In Process Research and Development [Member] | Lenalidomide Product [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			300
Actavis [Member] | Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		297	398
AUSTEDO [Member] | In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			211
Japan [Member] | Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			$ 165
United States [Member] | Actavis [Member] | Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		$ 30

Goodwill - Summary of Changes i

Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Jun. 30, 2022	Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2020
Goodwill [Line Items]
Beginning balance	[1]		$ 20,040		$ 20,624
Goodwill reclassified as assets to held for sale					(18)
Goodwill impairment		$ (745)	(2,045)		0	$ (4,628)
Goodwill acquired			12
Translation differences			(374)		(566)
Ending balance	[1]		17,633	[2]	20,040	20,624
North America [Member]
Goodwill [Line Items]
Beginning balance	[1]		6,474		6,473
Goodwill reclassified as assets to held for sale					0
Goodwill impairment			0
Goodwill acquired			0
Translation differences			(24)		1
Ending balance	[1]		6,450	[2]	6,474	6,473
Europe [Member]
Goodwill [Line Items]
Beginning balance	[1]		8,544		9,102
Goodwill reclassified as assets to held for sale					(7)
Goodwill impairment			0
Goodwill acquired			0
Translation differences			(242)		(551)
Ending balance	[1]		8,302	[2]	8,544	9,102
International Markets [Member]
Goodwill [Line Items]
Beginning balance	[1]		2,328		2,362
Goodwill reclassified as assets to held for sale					0
Goodwill impairment			(979)
Goodwill acquired			0
Translation differences			(10)		(34)
Ending balance	[1]		1,339	[2]	2,328	2,362
Other [Member]
Goodwill [Line Items]
Beginning balance	[1]		2,694		2,687
Goodwill reclassified as assets to held for sale					(11)
Goodwill impairment			(1,066)
Goodwill acquired			12
Translation differences			(98)		18
Ending balance	[1]		$ 1,542	[2]	$ 2,694	$ 2,687
[1]Accumulated goodwill impairment as of December 31, 2022, December 31, 2021 and December 31, 2020 was approximately $27.6 billion, $25.6 billion and $25.6 billion, respectively.[2]As of December 31, 2022, “Other” includes $1,293 million goodwill balance related to Teva’s API reporting unit.

Goodwill - Summary of Changes_2

Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) - USD ($) $ in Millions		Dec. 31, 2022		Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Line Items]
Accumulated goodwill impairment		$ 27,600			$ 25,600	$ 25,600
Goodwill	[1]	17,633	[2]		$ 20,040	$ 20,624
Tevas API Reporting Unit [Member]
Goodwill [Line Items]
Goodwill		$ 1,293		$ 266
[1]Accumulated goodwill impairment as of December 31, 2022, December 31, 2021 and December 31, 2020 was approximately $27.6 billion, $25.6 billion and $25.6 billion, respectively.[2]As of December 31, 2022, “Other” includes $1,293 million goodwill balance related to Teva’s API reporting unit.

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended			12 Months Ended
		Dec. 31, 2022		Jun. 30, 2022	Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2020
Goodwill [Line Items]
Goodwill	[1]	$ 17,633	[2]		$ 17,633	[2]	$ 20,040	$ 20,624
Reporting unit percentage of fair value in excess of carrying amount				9%
Goodwill impairment				$ 745	2,045		$ 0	$ 4,628
Measurement Input Terminal Growth Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount				1.41%
Measurement Input, Discount Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount				10.04%
International Markets Reporting Unit [Member]
Goodwill [Line Items]
Goodwill				$ 479
Goodwill impairment		500
Tevas API Reporting Unit [Member]
Goodwill [Line Items]
Goodwill		1,293		$ 266	$ 1,293
Goodwill impairment		$ 800
Tevas Europe Reporting Unit [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount				5%
North America and Medis Reporting Units [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount				10%
Maximum [Member] | Measurement Input Terminal Growth Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount				0.91%
Maximum [Member] | Measurement Input, Discount Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount				10.54%
Minimum [Member] | Measurement Input Terminal Growth Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount				0.50%
Minimum [Member] | Measurement Input, Discount Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount				0.50%
[1]Accumulated goodwill impairment as of December 31, 2022, December 31, 2021 and December 31, 2020 was approximately $27.6 billion, $25.6 billion and $25.6 billion, respectively.[2]As of December 31, 2022, “Other” includes $1,293 million goodwill balance related to Teva’s API reporting unit.

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating lease cost:
Fixed payments and variable payments that depend on an index or rate	$ 142	$ 135	$ 148
Variable lease payments not included in the lease liability	4	4	4
Short-term lease cost	2	2	3
Total operating lease cost	$ 148	$ 141	$ 155

Leases - Supplemental cash flow

Leases - Supplemental cash flow information related to leases (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 140	$ 143	$ 151
Right-of-use assets obtained in exchange for lease obligations (non-cash):
Operating leases	$ 81	$ 81	$ 211

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related To Leases (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Operating leases:
Operating lease ROU assets	$ 419	$ 495
Other current liabilities	93	109
Operating lease liabilities	349	416
Total operating lease liabilities	$ 442	$ 525
Weighted average remaining lease term Operating leases	6 years 9 months 18 days	7 years 3 months 18 days
Weighted average discount rate Operating leases	5.60%	5.40%
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Liabilities, Current	Liabilities, Current

Leases - Maturities of lease l

Leases - Maturities of lease liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
2023	$ 116
2024	94
2025	79
2026	66
2027 and thereafter	188
Total operating lease payments	543
Less: imputed interest	101
Present value of lease liabilities	$ 442	$ 525

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2020
Finance Lease, Right-of-Use Asset	$ 29	$ 32
Finance Lease, Liability	$ 22	25
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other taxes and long-term liabilities
Operating lease right-of-use assets	$ 419	495
Operating lease liability	$ 442	$ 525
Maximum [Member]
Operating lease liability			$ 66
Minimum [Member]
Operating lease right-of-use assets			$ 74

Debt Obligations - Schedule of

Debt Obligations - Schedule of Short-term Debt (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Current maturities of long-term liabilities	$ 2,086	$ 1,403
Total short term debt	$ 2,109	1,426
Convertible debentures [Member]
Debt Instrument [Line Items]
Weighted average interest rate	0.25%
Maturity	2026
Short-term borrowings	$ 23	$ 23

Debt Obligations - Schedule o_2

Debt Obligations - Schedule of Senior Notes and Loans (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total senior notes		$ 21,266	$ 23,118
Less current maturities		(2,086)	(1,403)
Less debt issuance costs		(78)	(100)
Total senior notes and loans		19,103	21,617
Other Debentures [Member]
Debt Instrument [Line Items]
Total senior notes and loans		$ 1	2
Senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.13%
Maturity		2024
Total senior notes		$ 670	708
Sustainability-linked senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[1],[2]	4.38%
Maturity	[1],[2]	2030
Total senior notes	[1],[2]	$ 1,606	1,699
Senior notes EUR 1,300 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.25%
Maturity		2023
Total senior notes		$ 633	670
Sustainability-linked senior notes EUR 1,100 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[2],[3]	3.75%
Maturity	[2],[3]	2027
Total senior notes	[2],[3]	$ 1,177	1,246
Senior notes EUR 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6%
Maturity		2025
Total senior notes		$ 1,070	1,134
Senior notes EUR 900 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		4.50%
Maturity		2025
Total senior notes		$ 963	1,020
Senior notes EUR 750 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.63%
Maturity		2028
Total senior notes		$ 800	844
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[4]	3.25%
Maturity	[4]	2022
Total senior notes	[4]	$ 0	307
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.88%
Maturity		2027
Total senior notes		$ 748	792
Senior notes USD 3,500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		3.15%
Maturity		2026
Total senior notes		$ 3,496	3,496
Senior notes USD 3,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		2.80%
Maturity		2023
Total senior notes		$ 1,453	1,453
Senior notes USD 2,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		4.10%
Maturity		2046
Total senior notes		$ 1,986	1,986
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6%
Maturity		2024
Total senior notes		$ 1,250	1,250
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6.75%
Maturity		2028
Total senior notes		$ 1,250	1,250
Senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		7.13%
Maturity		2025
Total senior notes		$ 1,000	1,000
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[2],[3]	4.75%
Maturity	[2],[3]	2027
Total senior notes	[2],[3]	$ 1,000	1,000
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[1],[2]	5.13%
Maturity	[1],[2]	2029
Total senior notes	[1],[2]	$ 1,000	1,000
Senior notes USD 844 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[5]	2.95%
Maturity	[5]	2022
Total senior notes	[5]	$ 0	715
Senior notes USD 789 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6.15%
Maturity		2036
Total senior notes		$ 783	783
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[6]	0.50%
Maturity	[6]	2022
Total senior notes	[6]	$ 0	382
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1%
Maturity		2025
Total senior notes		$ 382	$ 383
[1]If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.[2]Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 10c.[3]If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.[4]In April 2022, Teva repaid $296 million of its 3.25% senior notes at maturity.[5]In December 2022, Teva repaid $713 million of its 2.95% senior notes at maturity.[6]In July 2022, Teva repaid $365 million of its 0.50% senior notes at maturity.

Debt Obligations - Schedule o_3

Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail) € in Millions, SFr in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CHF (SFr)	Jul. 31, 2022 USD ($)	Apr. 30, 2022 USD ($)
Senior Notes [Member]
Debt Instrument [Line Items]
Senior notes repaid amount		$ 713		$ 365	$ 296
Senior notes maturity percentage	2.95%	2.95%	2.95%	0.50%	3.25%
Senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	€ 1,500
Senior notes EUR 1,300 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	1,300
Senior notes EUR 900 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	900
Senior notes EUR 750 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	750
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	700
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	700
Senior notes EUR 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	1,000
Senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		$ 1,000
Senior notes USD 3,500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		3,500
Senior notes USD 3,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		3,000
Senior notes USD 2,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		2,000
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		1,250
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		1,250
Senior notes USD 844 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		844
Senior notes USD 789 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		789
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | SFr			SFr 350
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | SFr			SFr 350
Sustainability-linked senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	1,500
Sustainability-linked senior notes EUR 1,100 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	€ 1,100
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		1,000
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount		$ 1,000
Interest Rate Increase [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date	May 09, 2026
Interest Rate Increase [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)	0.375%
Interest Rate Increase [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)	0.125%
One Time Premium Payment [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date	May 09, 2026
One Time Premium Payment [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)	0.45%
One Time Premium Payment [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)	0.15%

Debt Obligation - Schedule Requ

Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Detail) $ in Millions	Dec. 31, 2022 USD ($)
Long Term Debt Maturity [Line Items]
2024	$ 1,921
2025	3,412
2026	3,523	[1]
2027	2,927
2028 and thereafter	7,448
Total	$ 19,231
[1]including $23 million convertible notes. See note 9a.

Debt Obligation - Schedule Re_2

Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Parenthetical) (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Convertible Debt [Member]
Short-term Debt [Line Items]
Principal amount currently outstanding on the debt instruments	$ 23	$ 23

Debt Obligations - Additional I

Debt Obligations - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended									12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long term debt currency portion USD									62%	62%
Long term debt currency portion EUR									36%	36%
Long term debt currency portion CHF									2%	2%
Convertible Debt [Member]
Debt Instrument [Line Items]
Principal amount currently outstanding on the debt instruments									$ 23	$ 23	$ 23
Weighted average interest rate									0.25%	0.25%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Description										The RCF can be used for general corporate purposes, including repaying existing debt. As of December 31, 2022 and as of the date of this Annual Report on Form 10-K, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued.
Long Term Debt Payable Under Revolving Credit Facility									$ 0	$ 0
Line of Credit Facility, Maximum Borrowing Capacity									$ 1,800	$ 1,800
Debt Instrument, Maturity Date										Apr. 30, 2026
Line of credit extension period										one-year
Revolving Credit Facility [Member] | Amended Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Leverage Ratio									4.25
Revolving Credit Facility [Member] | Amended Revolving Credit Facility [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Leverage Ratio	3.50	4.00	4.00	4.00	4.00	4.25	4.25	4.25

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) - Not Designated as Hedging Instrument [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Accounts Payable [Member]
Derivative [Line Items]
Liability derivatives	$ (101)	$ (23)
Other Current Assets [Member]
Derivative [Line Items]
Asset derivatives	$ 29	$ 30

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships (Details) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Comprehensive Income
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		$ (270)	$ (391)	$ (30)
Other Comprehensive Income | Net Investment Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	0	0	(21)
Financial expenses [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		966	1,058	834
Financial expenses [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	$ 0	$ 0	$ (2)
[1]In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva’s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3 million.

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Net Revenues [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		$ (14,925)		$ (15,878)		$ (16,659)
Net Revenues [Member] | Not Designated as Hedging Instrument, Trading [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	0		0		0
Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		(11)	[2]	(31)	[2]	0.5
Financial expenses [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		966		1,058		834
Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	(12)		(45)		130
Financial expenses [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[2]	$ 0		$ 0		$ 0
[1]Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.[2]Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Canadian dollar, Polish zloty and some other currencies to protect its projected operating results for 2022 and 2023. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2022, the positive impact from these derivatives recognized under revenues was $11 million. In 2021, the positive impact from these derivatives recognized under revenues was $31 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Derivative [Line Items]
Sold receivables at the beginning of the year	$ 685	$ 734
Proceeds from sale of receivables	4,653	5,139
Cash collections (remitted to the owner of the receivables)	(4,665)	(5,152)
Effect of currency exchange rate changes	(37)	(36)
Sold receivables at the end of the year	$ 636	$ 685

Derivative Instruments and He_7

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
	Nov. 07, 2022	Sep. 30, 2016	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2019
Derivative [Line Items]
Revenues other than USD			47%
Teva other comprehensive loss			$ 493
Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]			Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Forward starting interest rate swaps and treasury lock agreements losses			$ 30		$ 37		$ 31
Interest Rate Swap Gain			4		5		3
Deferred purchase asset			270		235
Sold receivables			636		685		734
Cash received on settlement of position			3
Derivative, Gain on Derivative			$ 11		31
Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]			Revenue from Contract with Customer, Excluding Assessed Tax
Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax			$ (11)	[1]	$ (31)	[1]	$ 0.5
Senior Notes Due 2023 Two [Member]
Derivative [Line Items]
Notional amount hedge debt		$ 3,000							$ 500
Previously hedge debt rate									2.80%
Cash received on settlement of position									$ 10
Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)		41
Senior Notes Due 2022 [Member]
Derivative [Line Items]
Notional amount hedge debt		$ 844
Previously hedge debt rate		2.95%
Senior Notes Due 2021 [Member]
Derivative [Line Items]
Notional amount hedge debt		$ 450						$ 588
Previously hedge debt rate		3.65%
Cash received on settlement of position								$ 95
Senior Notes Due 2020 [Member]
Derivative [Line Items]
Cash received on settlement of position			500
Senior Notes Due 2021 Two [Member]
Derivative [Line Items]
Previously hedge debt rate								3.65%
Accounts Receivable Securitization Facility [Member] | PNC Bank [Member]
Derivative [Line Items]
Sold receivables			436
Derivative notional amount	$ 1
Derivatives term of contract	3 years
Transfer of financial assets sold and derecognized			$ 820
Accounts Receivable Securitization Facility [Member] | PNC Bank [Member] | November 2025 [Member]
Derivative [Line Items]
Derivative notional amount decrease	$ 500
Accounts Receivable Securitization Facility [Member] | PNC Bank [Member] | November 2023 [Member]
Derivative [Line Items]
Derivative notional amount	$ 1,000
[1]Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Canadian dollar, Polish zloty and some other currencies to protect its projected operating results for 2022 and 2023. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2022, the positive impact from these derivatives recognized under revenues was $11 million. In 2021, the positive impact from these derivatives recognized under revenues was $31 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.

Legal Settlements and Loss Co_2

Legal Settlements and Loss Contingencies - Additional Information (Detail) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 EUR (€)
Loss Contingencies [Line Items]
Legal settlements and loss contingencies, expense	$ 2,082	$ 717	$ 60
Accrued amount for legal settlements and loss contingencies	$ 4,186	$ 2,710		€ 60.5
Settlement On Account Of Product Liability [Member] | United States [Member]
Loss Contingencies [Line Items]
Restructuring expense and income	Legal settlements and loss contingencies in 2021 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, the provision for the carvedilol patent litigation as well as a liability which was substantially offset by insurance receivable related to the Ontario Teachers Securities Litigation discussed in note 12b.

Commitments and Contingencies -

Commitments and Contingencies - Commitments - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Commitment And Contingencies [Line Items]
Royalty expense	$ 560	$ 522	$ 505
Maximum [Member]
Commitment And Contingencies [Line Items]
Milestone contingent expense	$ 26

Commitments and Contingencies_2

Commitments and Contingencies - Contingencies - Additional Information (Detail) € in Millions

1 Months Ended

9 Months Ended

12 Months Ended

48 Months Ended

Dec. 31, 2022 USD ($)

Nov. 30, 2022 USD ($)

Nov. 09, 2022 USD ($)

Jul. 12, 2022 USD ($)

May 24, 2022 USD ($)

Mar. 30, 2022 USD ($)

Mar. 21, 2022 USD ($)

Feb. 04, 2022 USD ($)

Aug. 05, 2021 USD ($)

Jul. 21, 2021 USD ($)

Feb. 11, 2021 USD ($)

Oct. 21, 2019 USD ($)

May 31, 2019 USD ($)

Sep. 30, 2013 USD ($)

Apr. 30, 2013 USD ($)

Aug. 31, 2012 USD ($)

Dec. 31, 2010 USD ($)

Sep. 30, 2021 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2019 USD ($)

Dec. 31, 2014 USD ($)

Aug. 21, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Jul. 08, 2021 USD ($)

Aug. 31, 2019 USD ($)

Jul. 31, 2008 USD ($)

Feb. 28, 2005 USD ($)

Commitment And Contingencies [Line Items]

Damages assessment

$ 235,500,000

$ 235,500,000

Annual sales at the time of settlement

700,000,000

700,000,000

$ 350,000,000

Annual sales of Effexor

$ 2,600,000,000

Annual sales of Lamictal

$ 2,300,000

$ 950,000,000

Annual sales of Niaspan

$ 1,100,000,000

$ 416,000,000

Annual sales of Actos

$ 2,800,000,000

$ 3,700,000,000

Annual sales of Acto plus

$ 430,000,000

$ 500,000,000

Litigation settlement amount

$ 4,250,000,000

Annual Sales Of Sensipar

$ 1,400,000,000

Litigation settlement amount awarded distribution period

13 years

Annual sales of Copaxone

$ 373,000,000

Generic modafinil, and imposed fines amount

4,186,000,000

4,186,000,000

€ 60.5

$ 2,710,000,000

Loss Contingency Accrual, Provision

$ 235,500,000

Annual sales of the time of settlement of viread

582,000,000

Annual sales of the time of settlement of Truvada

2,400,000,000

Annual sales of the time of settlement of Atripla

2,900,000,000

Annual sales of the time of New launch of viread

728,000,000

Annual sales of the time of New launch of Truvada

2,100,000,000

Annual sales of the time of New launch of Atripla

444,000,000

Annual sales of Colcrys

187,000,000

Litigation Settlement Amount DistributableIn Kind

$ 1,200,000,000

Accrual for Environmental Loss Contingencies

$ 300,000

$ 300,000

Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]

Other Liabilities, Noncurrent

Other Liabilities, Noncurrent

Other Liabilities, Noncurrent

Loss Contingencies On Environmental Laws Penalty

$ 1,400,000

Percentage of population of subdivisions will formally release as a part of settlement

96

Annual Sales Of Revlimid

$ 3,500,000,000

Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer

300,000,000

Annual Sales Of EpiPen

600,000,000

Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population

$ 1,000,000

Percentage Of Share Of The National Population

1%

Litigation Settlement Amount Awarded To Tribes

$ 100,000,000

Percentgae of amount in cash settlement

20%

Litigation Settlement Amount Distributable in cash

$ 240,000,000

Loss Contingency, Damages Awarded, Value

$ 176,500,000

Attorney General Of Louisana [Member]

Commitment And Contingencies [Line Items]

Litigation Settlement Amount DistributableIn Kind

$ 3,000,000

Attorney General Of Rhode Island [Member]

Commitment And Contingencies [Line Items]

Litigation Settlement Amount DistributableIn Kind

$ 78,500,000

Attorney General Of Florida [Member]

Commitment And Contingencies [Line Items]

Litigation Settlement Amount DistributableIn Kind

$ 84,000,000

Attorney General Of West Virginia [Member]

Commitment And Contingencies [Line Items]

Litigation Settlement Amount DistributableIn Kind

$ 27,000,000

City and Country Of San Francisco [Member]

Commitment And Contingencies [Line Items]

Litigation Settlement Amount DistributableIn Kind

$ 20,000,000

Four Other Defendants Other Than Teva Member

Commitment And Contingencies [Line Items]

Loss contingency payment

$ 26,000,000,000

Opioid Litigation [Member]

Commitment And Contingencies [Line Items]

Litigation settlement amount

$ 20,300,000

$ 75,000,000

$ 177,000,000

$ 21,000,000

$ 150,000,000

$ 15,000,000

$ 25,000,000

$ 85,000,000

Litigation settlement amount awarded cash amount

$ 20,000,000

Litigation settlement amount awarded cash amount distribution period

13 years

15 years

15 years

13 years

15 years

18 years

Opioid Litigation [Member] | Attorney General Of Louisana [Member]

Commitment And Contingencies [Line Items]

Litigation Settlement Amount DistributableIn Kind

$ 75,000,000

Nationwide Settlement [Member] | Four Other Defendants Other Than Teva Member

Commitment And Contingencies [Line Items]

Litigation settlement amount awarded distribution period

18 years

Europe [Member]

Commitment And Contingencies [Line Items]

Damage claimed

$ 50,000,000

Eosinophilic Esophagitis [Member]

Commitment And Contingencies [Line Items]

Damage claimed

200,000,000

Eosinophilic Esophagitis [Member] | United States [Member]

Commitment And Contingencies [Line Items]

Damage claimed

$ 150,000,000

AndroGel Rate at 1% [Member]

Commitment And Contingencies [Line Items]

Annual sales at the time of settlement

$ 140,000,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
Parent Company and its Israeli subsidiaries	$ (119)	$ 126	$ 947
Non-Israeli subsidiaries	(2,946)	532	(5,353)
Income (loss) before income taxes	$ (3,065)	$ 658	$ (4,406)

Income Taxes - Schedule of the

Income Taxes - Schedule of the Provision for Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
In Israel	$ 33	$ 124	$ 60
Outside Israel	(671)	87	(228)
Effective consolidated income taxes	(638)	211	(168)
Current	430	270	182
Deferred	(1,068)	(59)	(350)
Income tax expense (benefit)	$ (638)	$ 211	$ (168)

Income Taxes - Accumulated Othe

Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
Income (loss) before income taxes		$ (3,065)	$ 658	$ (4,406)
Statutory tax rate in Israel		23%	23%	23%
Theoretical provision for income taxes		$ (705)	$ 151	$ (1,013)
Increase (decrease) in the provision for income taxes due to:
The Parent Company and its Israeli subsidiaries - Tax benefits arising from reduced tax rates under benefit programs		15	(12)	(153)
Mainly nondeductible items and prior year tax		35	20	(30)
Non-Israeli subsidiaries, including impairments	[1]	924	117	1,369
Worthless stock deduction	[2]	(909)
Increase (decrease) in other uncertain tax positions—net		2	(65)	(341)
Effective consolidated income taxes		$ (638)	$ 211	$ (168)
[1]In 2022 and 2020, loss before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect.[2]In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva will recognize on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million.

Income Taxes - Accumulated Ot_2

Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
Obsolete stock written off	$ 4,200
Effective income tax reconciliation amount inventory written off	$ 909	[1]
[1]In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva will recognize on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million.

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Defered Income Taxes (Detail) - USD ($) $ in Millions		Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets Liabilities Net [Line Items]
Inventory related		$ 125	$ 104
Sales reserves and allowances		89	136
Provision for legal settlements		703	360
Intangible assets	[1]	(567)	(814)
Carryforward losses and deductions and credits	[2]	2,850	2,093
Property, plant and equipment		(238)	(215)
Deferred interest		800	617
Provisions for employee related obligations		82	95
Other		133	159
Long-term deferred tax assets (liabilities)-gross		3,977	2,535
Valuation allowance—in respect of carryforward losses and deductions that may not be utilized		(3,072)	(2,723)
Deferred tax assets liabilities net		$ 905	$ (188)
[1]The decrease in deferred tax liability is mainly due to impairment and amortization.[2]The amounts are shown following a reduction for unrecognized tax benefits of $1 million and $10 million as of December 31, 2022 and 2021, respectively.

Income Taxes - Schedule of De_2

Income Taxes - Schedule of Defered Income Taxes (Parenthetical) (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets Liabilities Net [Line Items]
Unrecognized tax benefits	$ 1	$ 10

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) ₪ in Millions, $ in Millions		1 Months Ended		12 Months Ended
	Jan. 01, 2017	Oct. 31, 2021 USD ($)	Jul. 31, 2020 USD ($)	Dec. 31, 2022 USD ($) Employee	Dec. 31, 2022 ILS (₪) Employee	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2016
Income Tax [Line Items]
Balance of accrued potential penalties and interest in unrecognized tax benefits				$ 212		$ 210	$ 173
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense				$ 2		$ 37	$ 9
Statutory tax rate in Israel				23%	23%	23%	23%
Annual revenue				$ 14,925		$ 15,878	$ 16,659
Expected impairment of income tax benefit			$ 127
Israel Tax Authority [Member]
Income Tax [Line Items]
Withholding tax percentage on dividends								8%
Israel Tax Authority [Member] | Tax Year 2008 To 2011 [Member]
Income Tax [Line Items]
Income Tax Examination, Estimate of Possible Loss		$ 350
Tax Carryforwards And Deductions Expiration Period One [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				98
Tax Carryforwards And Deductions Expiration Period Two [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				950
Tax Carryforwards And Deductions No Expiration [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				60
Tax Carryforwards And Deductions Indefinite [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				1,742
Amendment 69 to Investment Law [Member]
Income Tax [Line Items]
Payment of corporate tax				577
Exempt Income				9,400
Amendment 68 to Investment Law [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Statutory tax rate in Israel								16%
Amendment 68 to Investment Law [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Statutory tax rate in Israel								9%
Amendment 73 to Investment Law [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Statutory tax rate in Israel	7.50%
Preferred Enterprise [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Withholding tax percentage on dividends								20%
Preferred Enterprise [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Withholding tax percentage on dividends								5%
Preferred Technological Enterprises [Member]
Income Tax [Line Items]
Venture capital investment				$ 2
Average growth rate in sales or workforce				25%	25%
Average growth preceding period in sales or workforce				3 years	3 years
Preferred Technological Enterprises [Member] | Research and Development Arrangement [Member]
Income Tax [Line Items]
Minimum percentage of investment income				7%	7%
Minimum investment income				$ 22	₪ 75
Minimum percentage of workforce				20%	20%
Minimum number of employees employed | Employee				200	200
Preferred Technological Enterprises [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Statutory tax rate in Israel				12%	12%
Preferred Technological Enterprises [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Statutory tax rate in Israel				7.50%	7.50%
Special Preferred Technological Enterprise [Member]
Income Tax [Line Items]
Annual revenue				$ 2,900	₪ 10,000
Special Preferred Technological Enterprise [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Statutory tax rate in Israel				6%	6%
Withholding tax percentage on dividends				4%	4%
Minimum [Member] | Tax Carryforwards And Deductions Expiration Period One [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2023	Dec. 31, 2023
Minimum [Member] | Tax Carryforwards And Deductions Expiration Period Two [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2025	Dec. 31, 2025
Minimum [Member] | Tax Carryforwards And Deductions No Expiration [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2033	Dec. 31, 2033
Maximum [Member] | Tax Carryforwards And Deductions Expiration Period One [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2024	Dec. 31, 2024
Maximum [Member] | Tax Carryforwards And Deductions Expiration Period Two [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2032	Dec. 31, 2032

Income Taxes - Schedule of De_3

Income Taxes - Schedule of Deferred Tax Assets and Liabilities By Report Caption (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets Liabilities Net [Line Items]
Long-term assets—deferred income taxes	$ 1,453	$ 596
Long-term liabilities—deferred income taxes	(548)	(784)
Deferred tax assets liabilities net	$ 905	$ (188)

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Unrecognized Tax Benefits [Line Items]
Balance at the beginning of the year	$ 672	$ 888	$ 1,223
Increase (decrease) related to prior year tax positions, net	(46)	(106)	(238)
Increase related to current year tax positions	42	7	10
Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations	(31)	(115)	(105)
Other	1	(2)	(2)
Balance at the end of the year	$ 638	$ 672	$ 888

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions			12 Months Ended
	Jul. 13, 2017	Apr. 18, 2016	Dec. 31, 2022	Dec. 31, 2021	Jun. 11, 2020	Sep. 03, 2015	Jun. 29, 2010
Class of Stock [Line Items]
Ordinary shares issuance ADSs			1,200,000	1,200,000
Share price			$ 9.12
Number of shares exercisable			24,119
Number of shares available for future awards			74,000
Vesting period, description			The vesting period of the outstanding options and RSUs is generally between 1 to 4 years from date of grant. The vesting period of PSUs is generally 3 years from date of grant. The rights of ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of other ordinary shares of the Company. The contractual term of these options is primarily for ten years.
Unrecognized compensation cost before tax related to RSUs/PSUs			$ 181
Weighted average period			2 years 6 months
Unrecognized compensation costs related to employee stock options			$ 0
2010 Long-Term Equity-Based Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares exercisable							70,000
2015 Long-Term Equity-Based Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares exercisable	142,000	77,000				43,700
Number of additional shares authorized	65,000	33,300
2020 Long-Term Equity-Based Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares exercisable					68,000

Equity - Summary of Stock Optio

Equity - Summary of Stock Option Activity (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance outstanding at begining of year	29,015	35,234	40,064
Forfeited	(2,378)	(3,644)	(3,610)
Expired	(2,518)	(2,575)	(1,220)
Balance outstanding at end of year	24,119	29,015	35,234
Balance exercisable at end of year	24,119	26,989	28,556
Balance outstanding at begining of year	$ 36.96	$ 37.27	$ 37.9
Forfeited	33.77	36.09	40.24
Expired	41.26	42.4	49.35
Balance outstanding at end of year	36.83	36.96	37.27
Balance exercisable at end of year	$ 36.83	$ 38.3	$ 40.56

Equity - Schedule of Ordinary S

Equity - Schedule of Ordinary Shares Issued Upon Vested Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2022 yr $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	24,119
Weighted average exercise price	$ 36.83
Weighted average remaining life Years | yr	3.7
Lower than $15.01 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	592
Weighted average exercise price	$ 11.4
Weighted average remaining life Years | yr	4.84
Range of exercise prices, upper limit	$ 15.01
$15.01 - $25.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	7,781
Weighted average exercise price	$ 18.96
Weighted average remaining life Years | yr	5.13
Range of exercise prices, lower limit	$ 15.01
Range of exercise prices, upper limit	$ 25
$25.01 - $35.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	5,712
Weighted average exercise price	$ 34.61
Weighted average remaining life Years | yr	4.16
Range of exercise prices, lower limit	$ 25.01
Range of exercise prices, upper limit	$ 35
$35.01 - $45.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	509
Weighted average exercise price	$ 38.13
Weighted average remaining life Years | yr	0.57
Range of exercise prices, lower limit	$ 35.01
Range of exercise prices, upper limit	$ 45
$45.01 - $55.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	5,906
Weighted average exercise price	$ 51.3
Weighted average remaining life Years | yr	2.36
Range of exercise prices, lower limit	$ 45.01
Range of exercise prices, upper limit	$ 55
$55.01 - $65.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	3,619
Weighted average exercise price	$ 59.1
Weighted average remaining life Years | yr	2.33
Range of exercise prices, lower limit	$ 55.01
Range of exercise prices, upper limit	$ 65

Equity - Schedule of Number of

Equity - Schedule of Number of RSUs Issued and Outstanding (Detail) - Restricted Stock Units [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance outstanding at beginning of year	24,412	20,720	15,977
Granted	18,755	12,748	10,848
Vested	(7,571)	(6,818)	(4,324)
Forfeited	(3,293)	(2,238)	(1,781)
Balance outstanding at end of year	32,302	24,412	20,720
Weighted-average grant date fair value per share - RSUs at beginning year	$ 11.58	$ 13.81	$ 16.49
Granted	7.42	10.42	11.42
Vested	13.02	15.6	19.49
Forfeited	9.81	12.18	18.18
Weighted-average grant date fair value per share - RSUs at end of year	$ 9.11	$ 11.58	$ 13.81

Equity - Summary of Company Exp

Equity - Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock Options Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 2	$ 16	$ 30
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	122	103	99
Omnibus Long Term Share Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	124	119	129
Tax effect on stock-based compensation expense	9	12	14
Net effect	$ 115	$ 107	$ 115

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		$ (2,683)
Ending Balance		(2,838)	$ (2,683)
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(2,274)	(1,919)	$ (1,794)
Other comprehensive income/(loss) before reclassifications		(223)	(386)	(190)
Net other comprehensive income/(loss) before tax		(223)	(386)	(190)
Corresponding income tax		(17)	31	65
Net other comprehensive income/(loss) after tax	[1]	(240)	(355)	(125)
Ending Balance		(2,514)	(2,274)	(1,919)
Derivative Financial Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(324)	(363)	(420)
Other comprehensive income/(loss) before reclassifications				22
Amounts reclassified to the statements of income		29	39	35
Net other comprehensive income/(loss) before tax		29	39	57
Net other comprehensive income/(loss) after tax	[1]	29	39	57
Ending Balance		(295)	(324)	(363)
Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(85)	(117)	(98)
Other comprehensive income/(loss) before reclassifications		40	18	(7)
Amounts reclassified to the statements of income		27	18	(12)
Net other comprehensive income/(loss) before tax		67	36	(19)
Corresponding income tax		(10)	(4)	1
Net other comprehensive income/(loss) after tax	[1]	57	32	(18)
Ending Balance		(28)	(85)	(117)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(2,683)	(2,399)	(2,312)
Other comprehensive income/(loss) before reclassifications		(183)	(368)	(175)
Amounts reclassified to the statements of income		56	57	23
Net other comprehensive income/(loss) before tax		(127)	(311)	(152)
Corresponding income tax		(27)	27	66
Net other comprehensive income/(loss) after tax	[1]	(154)	(284)	(86)
Ending Balance		$ (2,838)	$ (2,683)	$ (2,399)
[1]Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $116 million loss in 2022, $107 million loss in 2021 and $56 million gain in 2020.

Equity - Accumulated Other Co_2

Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Foreign Currency Translation Adjustments Attributable to Non-controlling Interests [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation attributable to non-controlling interests	$ 116	$ 107	$ 56

Other assets impairments, res_3

Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring and Impairment Costs [Line Items]
Impairments of long-lived tangible assets	[1]	$ 47	$ 160	$ 416
Contingent consideration (see note 20)		163	7	(81)
Restructuring		146	133	120
Other		57	41	24
Total		$ 414	$ 341	$ 479
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]		Other asset impairments, restructuring and other items
[1]Including impairments related to exit and disposal activities.

Other assets impairments, res_4

Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 146	$ 133	$ 120
Employee termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	117	117	71
Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 29	$ 16	$ 49

Other assets impairments, res_5

Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Beginning balance		$ (138)	$ (122)	$ (215)
Provision		(146)	(133)	(120)
Utilization and other	[1]	165	117	213
Ending balance		(119)	(138)	(122)
Employee termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Beginning balance		(131)	(115)	(208)
Provision		(117)	(117)	(71)
Utilization and other	[1]	136	101	164
Ending balance		(112)	(131)	(115)
Other Exit and Disposal [Member]
Restructuring Cost and Reserve [Line Items]
Beginning balance		(7)	(7)	(7)
Provision		(29)	(16)	(49)
Utilization and other	[1]	29	16	49
Ending balance		$ (7)	$ (7)	$ (7)
[1]Includes adjustments for foreign currency translation.

Other assets impairments, res_6

Other assets impairments, restructuring and other items - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring and Impairment Costs [Line Items]
Impairments of property, plant and equipment	$ 47	$ 160	$ 416
Business combination contingent consideration arrangements change in amount of contingent consideration liability	163	7	(81)
Restructuring costs	146	$ 133	$ 120
Development Expense	$ 98

Other Income - Schedule of Othe

Other Income - Schedule of Other Income (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Income [Line Items]
Gain on divestitures, net of divestitures related costs	[1]	$ 46	$ 51	$ 8
Section 8 and similar payments	[2]	13	19
Gain (loss) on sale of assets		18	7	11
Other, net	[3]	31	22	20
Total other income		$ 107	$ 98	$ 40
[1]In 2022 mainly related to the devistment of several activities in North America and International market segments. In 2021, mainly due to capital gains related to the sale of certain OTC assets. In 2020 mainly related to the divestment of several activities in the International Markets segment.[2]Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada.[3]In 2022 mainly the result of settlement proceeds related to the International Markets segment.

Financial expenses, net - Sched

Financial expenses, net - Schedule of Financial Expenses (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Expenses [Line Items]
Interest expenses and other bank charges		$ 930	$ 891	$ 901
(Income) loss from investments	[1]	(10)	90	(104)
Foreign exchange (gains) losses, net		(16)	7	(26)
Other, net	[2]	61	71	62
Total finance expense, net		$ 966	$ 1,058	$ 834
[1](Income) loss from investments in 2021 and 2020 comprised mainly of revaluation gains and loss of Teva’s investment in American Well Corporation (“American Well”). See note 20.[2]Amortization of issuance costs and terminated derivative instruments.

Earnings (Loss) per Share - Sch

Earnings (Loss) per Share - Schedule of Earnings per Share (Detail) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net income (loss) used for the computation of basic and diluted earnings (loss) per share	$ (2,353)	$ 417	$ (3,990)
Weighted average number of shares used in the computation of basic earnings (loss) per share	1,110	1,102	1,095
Weighted average number of shares used in the computation of diluted earnings (loss) per share	1,110	1,107	1,095

Earnings (Loss) per Share - Add

Earnings (Loss) per Share - Additional Information (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Earnings per share, Basic	$ (2.12)	$ 0.38	$ (3.64)
Earnings per share, Diluted	$ (2.12)	$ 0.38	$ (3.64)
Weighted average shares with dilutive effect on earnings per share		5,000,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average shares with anti-dilutive effect on earnings per share		0	0

Segments - Summary of Segment P

Segments - Summary of Segment Profit (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	$ 14,925	$ 15,878	$ 16,659
Gross profit	6,973	7,594	7,726
R&D expenses	838	967	997
S&M expenses	2,265	2,429	2,498
G&A expenses	1,180	1,099	1,173
Segment profit	(2,099)	1,716	(3,572)
North America [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	7,452	7,809	8,447
Gross profit	3,926	4,226	4,489
R&D expenses	532	618	622
S&M expenses	941	988	1,013
G&A expenses	474	427	443
Other (income) expense	(15)	(31)	(10)
Segment profit	1,993	2,224	2,421
Europe [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	4,525	4,886	4,757
Gross profit	2,700	2,823	2,666
R&D expenses	213	244	247
S&M expenses	748	846	830
G&A expenses	246	244	261
Other (income) expense	(3)	(5)	(3)
Segment profit	1,496	1,494	1,331
International Markets [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	1,903	2,032	2,154
Gross profit	1,033	1,118	1,096
R&D expenses	72	68	70
S&M expenses	405	417	427
G&A expenses	119	109	136
Other (income) expense	(43)	(5)	(11)
Segment profit	$ 479	$ 529	$ 474

Segments - Summary of Profit by

Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Amounts allocated to segments:
Segments profit		$ (2,099)	$ 1,716	$ (3,572)
Amounts not allocated to segments:
Amortization		732	802	1,020
Other asset impairments, restructuring and other items		414	341	479
Intangible asset impairments		355	424	1,502
Goodwill impairment	$ 745	2,045	0	4,628
Legal settlements and loss contingencies		2,082	717	60
Other unallocated amounts		610	402	271
Consolidated operating income (loss)		(2,099)	1,716	(3,572)
Financial expenses, net		966	1,058	834
Income (loss) before income taxes		(3,065)	658	(4,406)
North America [Member]
Amounts allocated to segments:
Segments profit		1,993	2,224	2,421
Amounts not allocated to segments:
Consolidated operating income (loss)		1,993	2,224	2,421
Europe [Member]
Amounts allocated to segments:
Segments profit		1,496	1,494	1,331
Amounts not allocated to segments:
Consolidated operating income (loss)		1,496	1,494	1,331
International Markets [Member]
Amounts allocated to segments:
Segments profit		479	529	474
Amounts not allocated to segments:
Consolidated operating income (loss)		479	529	474
Corporate Segment [Member]
Amounts allocated to segments:
Segments profit		3,968	4,246	4,225
Amounts not allocated to segments:
Consolidated operating income (loss)		3,968	4,246	4,225
Other Segments [Member]
Amounts allocated to segments:
Segments profit		172	154	163
Amounts not allocated to segments:
Consolidated operating income (loss)		172	154	163
Segments and Other Activities [Member]
Amounts allocated to segments:
Segments profit		4,140	4,401	4,388
Amounts not allocated to segments:
Consolidated operating income (loss)		$ 4,140	$ 4,401	$ 4,388

Segments - Schedule of Revenues

Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
Revenues	$ 14,925	$ 15,878	$ 16,659
North America [Member]
Product Information [Line Items]
Revenues	7,452	7,809	8,447
Europe [Member]
Product Information [Line Items]
Revenues	4,525	4,886	4,757
International Markets [Member]
Product Information [Line Items]
Revenues	1,903	2,032	2,154
Generic products [Member] | North America [Member]
Product Information [Line Items]
Revenues	3,549	3,769	4,010
Generic products [Member] | Europe [Member]
Product Information [Line Items]
Revenues	3,466	3,569	3,513
Generic products [Member] | International Markets [Member]
Product Information [Line Items]
Revenues	1,586	1,649	1,792
AJOVY [Member] | North America [Member]
Product Information [Line Items]
Revenues	218	176	134
AJOVY [Member] | Europe [Member]
Product Information [Line Items]
Revenues	124	87	31
AJOVY [Member] | International Markets [Member]
Product Information [Line Items]
Revenues	35	50	18
AUSTEDO [Member] | North America [Member]
Product Information [Line Items]
Revenues	963	802	637
BENDEKA and TREANDA [Member] | North America [Member]
Product Information [Line Items]
Revenues	316	385	415
COPAXONE [Member] | North America [Member]
Product Information [Line Items]
Revenues	387	577	884
COPAXONE [Member] | Europe [Member]
Product Information [Line Items]
Revenues	268	391	400
COPAXONE [Member] | International Markets [Member]
Product Information [Line Items]
Revenues	36	37	53
Anda [Member] | North America [Member]
Product Information [Line Items]
Revenues	1,471	1,323	1,462
Respiratory Product [Member] | Europe [Member]
Product Information [Line Items]
Revenues	273	356	353
Other [Member] | North America [Member]
Product Information [Line Items]
Revenues	549	777	905
Other [Member] | Europe [Member]
Product Information [Line Items]
Revenues	393	483	459
Other [Member] | International Markets [Member]
Product Information [Line Items]
Revenues	$ 246	$ 295	$ 291

Segments - Schedule of Sales Pe

Segments - Schedule of Sales Percentage by Therapeutic Category (Detail)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
McKesson Corporation [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Third party net sales present	10%	11%	12%
AmerisourceBergen Corporation [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Third party net sales present	10%	11%	12%

Segments - Schedule of Net Sale

Segments - Schedule of Net Sales by Product Line - Schedule of Property, Plant and Equipment by Geographic Location (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 5,739	$ 5,982
Israel [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,401	1,543
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,143	1,045
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	625	692
Croatia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	445	481
Czech republic [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	318	324
Hungary [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	294	321
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	268	269
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 1,245	$ 1,307

Segments - Additional Informati

Segments - Additional Information (Detail) - Segment	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Number of reportable segments	3
Israel [Member] | Sales Revenue, Net [Member] | Revenue from Rights Concentration Risk [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	2%	2%	2%
UNITED STATES | Sales Revenue, Net [Member] | Revenue from Rights Concentration Risk [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	47%	46%	48%

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) - USD ($) $ in Millions		Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash		$ 33	$ 33
Contingent consideration	[1]	(153)	(176)
Total		$ 2,624	2,054
Derivative Asset, Statement of Financial Position [Extensible Enumeration]		Other Assets, Current
Derivative Liability, Statement of Financial Position [Extensible Enumeration]		Other Liabilities, Current
Asset Derivatives - Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		$ 29	30
Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		0
Liabilities Derivatives Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		(101)	(23)
Money Markets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		1,222	220
Cash, Deposits and Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		1,579	1,945
Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		9	18
Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		6	7
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash		33	33
Total		2,848	2,222
Level 1 [Member] | Money Markets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		1,222	220
Level 1 [Member] | Cash, Deposits and Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		1,579	1,945
Level 1 [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		9	18
Level 1 [Member] | Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		5	6
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		(73)	7
Level 2 [Member] | Asset Derivatives - Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		29	30
Level 2 [Member] | Liabilities Derivatives Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		(101)	(23)
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	[1]	(153)	(176)
Total		(152)	(175)
Level 3 [Member] | Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		$ 1	$ 1
[1]Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.

Fair value measurement - Additi

Fair value measurement - Additional Information (Detail)	Dec. 31, 2022
Maximum [Member] | Measurement input probability of success [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	100
Maximum [Member] | Measurement input, discount rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	11
Minimum [Member] | Measurement input probability of success [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	90
Minimum [Member] | Measurement input, discount rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	8.5
Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	8.9

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value at the beginning of the period	$ (175)	$ (258)
Redemption of debt securities	0	(9)
Fair value at the end of the period	(152)	(175)
Nove Tide Acquisition [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Redemption of debt securities	(11)	0
Actavis Generics [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Actavis Generics transaction	(142)	15
Settlement of contingent consideration	109	100
Eagle Transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Adjustments to provisions for contingent consideration	(21)	(23)
Settlement of contingent consideration	$ 88	$ 0

Fair Value Measurement - Summ_3

Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)	Jan. 01, 2022
Nove tide Acquisition [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition, Percentage of voting interests acquired	100%

Fair Value Measurement - Summ_4

Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 18,769	$ 22,903
Senior Notes And Sustainability Linked Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	16,694	21,477
Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 2,075	$ 1,426

Long-term Employee-related Ob_3

Long-term Employee-related Obligations - Schedule of Long Term Employee Related Obligation (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Accrued severance obligations	$ 74	$ 83
Defined benefit plans	58	142
Total	$ 132	$ 225

Long-term Employee-related Ob_4

Long-term Employee-related Obligations - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Long-term investments earmarked for severance pay liabilities in Israel	$ 79	$ 97
Expected contributions to pension funds	111
2023	14
2024	12
2025	12
2026	13
2027	13
2028 to 2032	$ 76

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	$ 4,309	$ 4,904
Deductions	(13,513)	(14,036)
Balance at end of period	3,817	4,309	$ 4,904
Allowance For Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	164	200	209
Charged to costs and expenses	8	(8)	(11)
Charged to other accounts	(2)	0	2
Deductions	(8)	(28)	0
Balance at end of period	162	164	200
Valuation Allowance in Tax Carryforward Losses And Deductions [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	2,723	2,547	1,974
Charged to costs and expenses	443	336	670
Deductions	(93)	(160)	(97)
Balance at end of period	$ 3,072	$ 2,723	$ 2,547